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Documenting healthcare, along with technology enabling capture of streaming 
patient telemetry, can deliver large datasets offering opportunities to discover new 
insights primarily identified through retrospective secondary use research. 
Research involving health data requires consent of the subject patient or 
someone with the power to speak on that patient’s behalf. Flexible consent 
models that capture consent preferences while allowing updates as preferences 
change are needed. This research proposes and demonstrates one solution in a 
case study collecting surrogate consent from parents for the physiological data of 
infant inpatients in the Neonatal Intensive Care Unit (NICU) and attaching this 
consent as a wrapper controlling access to their data. 145 parents were 
approached and 134 provided consent: with 78 percent of infants consented 
during their first week of life. This research supports the contention that using a 
flexible consent approach enhances willingness to consent use of infant’s health 
data for secondary research purposes. 
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1. Introduction  
Florence Nightingale helped to transform healthcare through the introduction 
of formal and descriptive clinical documentation that would become a vital 
component of effective care delivery (Iyer & Camp, 1995). Clinical documentation 
serves many purposes, with the most significant being to ensure continuity and 
quality of care for the subject patient (Fischbach, 1991; Iyer & Camp, 1995).  
Modern practice incorporates technological devices into the care process that 
are capable of displaying continuous real-time data streams on various aspects of 
the patient’s physiological state. These devices are capable of recording these 
observations with much higher fidelity than could be documented by the care team, 
who may only do so twice hourly, hourly, or four hourly (Considine, Trotter, & 
Currey, 2016; Sriwatanakul et al., 1983). Variations in measured physiological 
parameters are common in the critically ill, but observations documented too 
infrequently may not make obvious the onset of potentially dangerous disease 
processes. While most medical devices are capable of reporting and storing the 
data as it is acquired, even many times per second, hospitals generally do not or 
are unable to capture the data and it is ultimately lost. Thus, the data is unavailable 
for further analysis because the monitoring device is not connected to an 
appropriate network or data storage systems. If healthcare professionals had 
access to clinical decision support systems (CDSS) that could source datasets of 
high-frequency observational data for analysis, there is greater potential for earlier 
recognition of the deteriorating patient. This recognition is vital for increasing 
patient safety and reducing the significant harm that results from potentially serious 
adverse health events (Cardona-Morrell et al., 2016; Lister, Bryan, & Tracy, 2000; 
McGregor, James, et al., 2013; van Veen, 2008)  
Recent studies on neonatal health conditions have demonstrated the 
potential of continuous real-time physiological data streams, with one study, Late 
Onset Neonatal Sepsis (LONS), providing an example for how large collections of 
physiological data could be used in predictive modelling (Fairchild, 2013; 




always a secondary use of that data with the primary use of the data for the care 
of the patient (McLachlan et al., 2018). 
Secondary use of medical records is an important means of scientific investigation, 
supporting a wide range of research including epidemiology, public health, drug 
surveillance and the design of decision support systems (Miller, 2008; Neamatullah 
et al., 2008; Weiskopf, Hripcsak, Swaminathan, & Weng, 2013).  
Research often relies on secondary use of patient data which, unless it has 
been anonymized with disclosure permitted by a research ethics board waiver, 
requires consent from every individual subject (Willison et al., 2007). Informed 
consent is a communication process between the patient/participant and the 
clinician/clinical researcher. Competent adults and Gillick competent minors, who 
are determined under medical law to be able to consent on their own behalf, are 
advised of the clinical test or treatment recommendation and related risks and 
benefits, and are given an opportunity to ask questions prior to providing 
agreement or permission for those tests or treatments to occur (American Cancer 
Society, 2019). 
In the current privacy-concerned age patients prefer to be involved in the 
decision to undertake research involving the use of their personal medical records 
(Lunshof, Chadwick, Vorhaus, & Church, 2008; Nair, Willison, Holbrook, & 
Keshavjee, 2004; Robling et al., 2004; Sanderson et al., 2017; Willison et al., 
2009). Patients often want to know when and why their medical records are being 
accessed, and to have the opportunity to consent or decline participation in such 
research (Nair et al., 2004; Robling et al., 2004). 
Conventional consent for research participation is most often achieved 
through the researcher explaining the purpose and degree of participation required 
for a particular study. Different consent models have been described and may be 
in clinical use, and while they are meant to reduce the consenter’s stress and 
decision-making burden, in situations involving children, and in particular infants, 
many do not consider parental autonomy and, in some cases, may not result in 
valid informed consent (Golec, Gibbins, Dunn, & Hebert, 2004). In some cases, if 




to engage the child in treatment or research without seeking consent and 
potentially against the wishes of the parents (McHaffie, Laing, Parker, & McMillan, 
2001) or limit parental decision-making authority if the parents’ decision is not in 
the infant’s “best interest” although this would primarily be based on the healthcare 
professional’s judgment of “best interest” (Albersheim, Lavoie, & Keidar, 2010). 
One study that offered hypothetical scenarios found that neonatologists would limit 
parental decision-making authority in situations where there was a clear treatment 
benefit (i.e. greater than 50% chance of intact survival or survival without severe 
handicap), but only up to 18% of them would limit parental decision-making 
authority despite a very poor chance of intact survival for a preterm neonate 
(Albersheim et al., 2010). When treatment is either clearly beneficial or clearly of 
no benefit, parental decision-making typically follows the medical estimate of the 
baby's best interest, based on the neonate’s threshold of viability even though the 
neonatologists' self-rated respect for parental decision-making authority was 8/10 
(Albersheim et al., 2010). Healthcare professionals may even approach internal 
ethics review boards and family courts, seeking a higher authority’s approval in 
overriding the parent’s views (Kopelman & Kopelman, 2007). The use of a less 
pressuring, more open, and informative approach to obtaining consent may make 
it easier to approach parents. 
Obtaining informed consent presents ethical and legal difficulties with certain 
groups of people or in situations requiring proxy consent (Burgess, Singhal, Amin, 
McMillan, & Devrome, 2003; Canadian Institutes of Health Research, 2005; 
Mason, 1997). This includes conducting neonatal research in the neonatal 
intensive care unit (NICU) environment with premature or ill term infants. The law 
acknowledges that young children and neonates are not competent to 
communicate their opinions concerning medical treatment and research 
participation, and allows proxy or surrogate consent from their parents or 
caregivers as a way of ensuring family values, preferences and parental discretion 
are all considered (Burgess et al., 2003; Canadian Institutes of Health Research, 
2005; Committee on Bioethics, 1995; Cooke, 2005; Golec et al., 2004; Mason, 




1.1 Background and Motivation 
Health records are created to record and inform clinical care; this is termed 
the primary use (Sandhu, Weinstein, McKethan, & Jain, 2012). When health 
records are used for purposes unrelated to care delivery, including research, 
analysis, quality and safety measurement, payment, provider accreditation or for 
other commercial activities; these are termed a secondary use (Safran et al., 
2007). Secondary use of health records plays an essential role in expanding 
current knowledge and understanding of treatment and health care delivery (Black, 
2003; Safran et al., 2007). A body of research reports the general public’s feeling 
of support for secondary use of their anonymized health data as long as they are: 
consulted as part of the process; provided with information about the research 
being undertaken; and given the option to approve their own participation 
(Damschroder et al., 2007; Kim, Joseph, & Ohno-Machado, 2015; Nair et al., 2004; 
Sanderson et al., 2017; Vermeulen, Schmidt, Aaronson, Kuenen, & van Leeuwen, 
2009; Willison et al., 2009). This is exemplified in the outcome for secondary use 
of Guthrie cards collected as part of the newborn screening (NBS) program. Card 
reuse received negative public attention and was the subject of a successful 
lawsuit after unconsented release for secondary research by a public health 
department (Cunningham, O'Doherty, Senecal, Secko, & Avard, 2015).  
We were unable to identify any prior investigations specifically assessing 
public perceptions for physiological data captured from infants for secondary use. 
This data has the potential to reveal important health knowledge about an 
individual, and prevent unnecessary death (Blount et al., 2010; McGregor, 2013; 
Pinsky & Dubrawski, 2014; Saria, Rajani, Gould, Koller, & Penn, 2013). Unless 
protected through vigilance and adherence, it is possible that any patient record, 
whether a screening blood sample or a collection of neonatal physiological data, 
could be exploited later in the subject infant’s life (Cunningham et al., 2015; 
Ramshaw, 2010). 
The primary motivation for this research was to address multiple limitations 
in existing research recruitment and consent models in areas relating to 




participants, yet relies on traditional one-time blanket consent to encompass 
potential and unknown future uses (Kaye et al., 2012; Kaye et al., 2015). We 
contend that blanket consent models should not be considered as true and 
meaningful informed consent as it is impossible to inform the participant of a future 
use that is unknown at the time consent was given, and users of blanket consent 
approaches may be reticent to approach participants a second time for fear that 
the person may withdraw consent (Kaye et al., 2012; Kaye et al., 2015). 
Information technology (IT) based participant-centered initiatives (PCI) that assist 
in capturing the informed consent event, with ongoing support for participant 
engagement and communication is an area of open research. The recently 
updated Australian National Health and Medical Research Council (NHMRC) 
National Statement of Ethical Conduct in Human Research identifies three types 
of consent around the use of data: 1) specific, 2) extended or 3) unspecified. 
‘Unspecified’ is defined as given for the use in any future research. Unspecified 
needs to include agreement for data to be included in a ‘databank’ for future use 
(The National Health and Medical Research Council, The Australian Research 
Council and Universities Australia, & Commonwealth of Australia, 2007 (Updated 
2018)). 
Systemic approaches towards secondary use of medical data could include 
health informatics infrastructure and associated data mining tools, such as Artemis 
and Service based Multidimensional Temporal Data Mining Framework (STDMn0). 
McGregor et al. (2011) proposed a clinical decision support system that enables 
multi-dimensional temporal abstraction and data mining. This system is known as 
the STDMn0 (McGregor, Catley, & James, 2011; McGregor et al., 2012; McGregor, 
Smith, & Dhanoa, 2013). STDMn0 has been instantiated within the knowledge 
discovery component of Artemis. Artemis is a high frequency, multisource, real 
time, online health analytics platform developed through a collaboration between 
the University of Ontario Institute of Technology (Ontario Tech University) and the 
IBM T.J Watson Research Center (Blount et al., 2010; McGregor, 2017). This data 
intensive platform allows for concurrent multi-patient, multi-diagnosis and multi-




support and ongoing research (McGregor, 2013). Artemis obtains high frequency 
physiological data from neonatal monitors that are located at the infant’s bedside 
along with other clinical information. The information can be simultaneously 
processed and returned, or stored for later analysis (McGregor, 2013, 2017; Pugh 
& McGregor, n.d.). Several research studies have been performed to date utilizing 
Artemis. Examples of neonatal research using Artemis include late onset neonatal 
sepsis (LONS) (McGregor, Catley, Padbury, & James, 2013), apnoea of 
prematurity (Thommandram, Eklund, & McGregor, 2013; Thommandram, Eklund, 
McGregor, Pugh, & James, 2014), anemia of prematurity (Pugh, Keir, McGregor, 
& James, 2013), premature infant pain (Naik, Bressan, James, & McGregor, 2013) 
and sleep wake cycle detection (Eklund et al., 2014).  
At present, the STDMn0 framework and its instantiation within Artemis does 
not support flexible or ongoing consent, nor does it encourage longitudinal parent 
and caregiver engagement with the research process. Few research IT 
approaches encourage individual participation in research, or support ongoing 
engagement and communication between participants and researchers (Kaye et 
al., 2012; Kaye et al., 2015). Developments in participant-centered initiatives (PCI) 
and REB requirements for patient and public involvement (PPI) are changing this.  
Two models described in the literature that seek to meet the need for flexible 
and ongoing consent are dynamic consent (DC) (Kaye et al., 2015) and meta 
consent (MC) models (Ploug & Holm, 2015a, 2016). The DC model is a PCI 
approach that supports participant engagement (Kaye et al., 2015). MC is any 
flexible consent model providing individuals an ability to choose how and when 
they consent to future secondary use of their retrospective or prospective biological 
samples or health information. PCIs can address some of the ethical and legal 
challenges that result from continual advancement and innovation, while ensuring 
the protection of research participants (Kaye et al., 2012). 
 
1.2 Research Problem   
The efficient use of valuable patient data requires a consent model that 




health data. Limited research attention has investigated approaches for surrogate 
ongoing flexible consent for the collection of real-time physiometric data that can 
subsequently be used for secondary research. This thesis investigates existing 
and potential consent models seeking a solution that is capable of offering the 
functionality necessary to enable flexible and longitudinal surrogate consent. 
 
1.3 Research Aim and Objectives 
Research Aim:  
This thesis investigates consent models applicable to circumstances using 
streaming physiological data from neonatal patients for secondary use. A 
secondary aim relates to the instantiation of a suitable consent model within a 
NICU context.  
 
Research Objectives:  
The research objectives are to: 
1) Create a flexible multi-level participant consent model that enables 
changing consent preferences longitudinally and the ability for surrogate 
consent;  
2) Enable that consent model to be integrated within database 
infrastructures that enable secondary use of data research studies that 
analyzes streams of data collected from sensors in relation to patient 
care; 
3) Instantiate that model within a research database; 
4) Demonstrate the use of that model within an ethically approved secondary 
use of data research clinical case study where surrogate consent is 
required.  
1.4 Research Method 
Constructive research is the method of choice for the research presented in 
this thesis. The constructive research method is a systematic approach that allows 
for the meaningful creation of methods, modules, techniques and tools, that have 




which their creation was originally intended for (McGregor, 2018). This research 
approach is widely used in technical science, mathematics, operations analysis, 
and clinical medicine (Kasanen, Lukka, & Siitonen, 1993). The method seeks to 
produce constructions based on the use of existing knowledge in novel ways, 
raising the possibility of incorporation of missing links in a manner that, as 
represented in Figure 1, bridges knowledge gaps between academia and practice 
(Crnkovic, 2010; Kasanen et al., 1993; Lehtiranta, Junnonen, Kärnä, & Pekuri, 
2015). The aim of constructive research is to solve a practical problem such that 
knowledge can be generated about how the problem can be solved, understood, 
explained or modeled in principle while producing an academically appreciated 
theoretical contribution within a specific domain (Crnkovic, 2010; Lehtiranta et al., 
2015). The research should address several related knowledge problems, with 
regards to feasibility, improvement and innovation (Crnkovic, 2010). 
 
 
Figure 1: Potential for a constructive research contribution.  
Adapted from: (Lehtiranta et al., 2015). 
 
Constructs generally refer to entities which develop solutions to explicit 
problems (Kasanen et al., 1993). A construct may be practical, theoretical or both 
practical and theoretical in nature (Crnkovic, 2010). Examples of constructs include 
processes, practices, tools or artifacts such as models, diagrams, organization 
charts, plans, algorithms and artificial languages, system designs and software 
development methods (Crnkovic, 2010; Lehtiranta et al., 2015). The theoretical 
significance of the construct should be highlighted (Crnkovic, 2010). The 




particularly in situations where it differs significantly from anything that existed prior 
to its creation (Kasanen et al., 1993). This allows for comparison of the new reality 
against the pre-existing one (Crnkovic, 2010). The constructive approach divides 
the research process into the following steps (Kasanen et al., 1993; Lehtiranta et 
al., 2015):  
1. The selection of a practically relevant problem, which also has research 
potential 
2. Obtain a general and comprehensive understanding of the topic 
3. Innovate (i.e. construct one or more applicable solutions to the problem) 
4. Demonstrate the solution’s feasibility 
5. Show the theoretical connections and the research contribution of the 
solution concept (i.e. linking the results back to the theory and 
demonstrating their practical contribution) 
6. Examine the scope of applicability of the solution (i.e. examine whether 
the results can be generalized) 
A summary of the Constructive Research Phases as they relate to research 
informing the Consent of Infants for Neonatal Secondary-use research (CoINS) 




Consent of Infants for Neonatal Secondary-use (CoINS) 
 Constructive Research 
1) Selection of a  
practically relevant 
problem which also 
has research 
potential 
Provide a new consent approach/model that offers participants and 
surrogate consenters adaptable and flexible consent, both initially, and 
longitudinally, in retrospective and prospective clinical research studies 
that involve the secondary use of physiological data     




● Understanding the current state of consent models used for 
retrospective and prospective clinical research 
● Understanding of the current state of surrogate consent models 





● Understand the current state of secondary use of physiological 
data methods, systems and tools from a perspective of their 
integration of consent models  
3) Innovate  ● A flexible, multi-level participant consent model that allows for the 
dictation of consent preferences regarding if and how health data 
can be used for clinical research is proposed. In addition, this 
model needs to support changing consent preferences 
longitudinally and the ability for surrogate consent  
● Integrate that consent model within a database infrastructure that 
enables secondary use of data research studies that analyzes 
streams of data collected from sensors in relation to patient care 
● Instantiate that model within a research database 
● Demonstrate the use of that model within an ethically approved 
secondary use of data research study where surrogate consent is 
required. 
4) Demonstrate that 
the solution works 
● This consent model is an extension of the current STDMn0 data 
model, providing surrogate consenters with the ability to dictate 
their consent preferences regarding if and how their infant’s 
collected physiological data can be used for clinical research. 
● The extension of the current STDMn0 data model has been 
instantiated within the Artemis platform database  
● This new consent model and extended data model that stores the 
consent information has been used within a retrospective LONS 
case study using an instantiation of the STDMn0 data model within 
the Artemis database  
5) Show the 
theoretical 
connections and the 
research 
contribution of the 
solution concept 
● Contributions to health informatics in the areas of consent, and 
(temporal) data mining by implementing a flexible consenting 
construct within the current STDMn0 data model 
● Contributions to medicine in the area of consent, medical 
research and (surrogate) patient engagement by providing 
research participants the ability to offer flexible consent 
● Contribution to medicine through the use of this consent model in 
the LONS research study 
6) Examine the 
scope of 
The consent model can be applicable to activities that require consent 




applicability of the 
solution 
 
Table 1: Constructive Research Phases in relation to the creation of the Consent of Infants for Neonatal 
Secondary-use research (CoINS) model  
Adapted from (McGregor, 2018) 
 
1.5 Thesis Structure 
This thesis is structured as follows:  
• Chapter 2 presents a literature review scoped to include the secondary use 
of medical data with a focus on physiological data, public perspectives of 
such secondary use, and consent models that are currently used in medical 
and research practice. 
• Chapter 3 introduces the NICU environment, a discussion of the value of 
and parental attitudes towards neonatal research, and the concept of 
delayed consent followed by a background of Late Onset Neonatal Sepsis 
(LONS), a common and serious condition affecting preterm infants. 
• Chapter 4 presents a description of the present state STDMn0 framework 
and the extension of STDMn0 to enable flexible, longitudinal and surrogate 
consent as well as the ability to tie consent data with research data. This is 
followed by an introduction to the Artemis platform and the instantiation of 
the STDMn0 framework within that. Finally, the extension of the Artemis to 
enable flexible collection of surrogate consent is presented.  
• Chapter 5 identifies the data elements that need to be captured for consent 
by identifying the functional requirements. This is accomplished via the 
inclusion of additional tables as an extension to the current STDMn0. 
• Chapter 6 contains a case study that examines how the flexible, longitudinal 
and surrogate consent model will work for a retrospective LONS research 
study in the NICU environment.  
• Chapter 7 presents a discussion arising from the results in chapter 6 
including how specified functional requirements were addressed and met. 
The chapter also reviews changes to and limitations of the study as well as 




• Chapter 8 reiterates the thesis contributions, identifies areas for future work 





2. Literature Review  
This chapter presents a literature review that examines informed consent with 
a focus on how consent applies to the secondary use of health data, and public 
perceptions of such uses. Secondary use of health data requires valid informed 
consent. The primary focus is on medical data, specifically streaming physiological 
data as captured from medical devices. The insights that might be revealed in 
physiological data remain largely unknown, however with increased interest in the 
real-time analysis of physiological data there are biometrical and privacy concerns 
that need addressing. Background information regarding the history and value of 
informed consent is introduced, followed by the concept of proxy and longitudinal 
consent, information technology consent tools to support the need for a flexible 
multi-level participant consent model that enables changing consent preferences 
longitudinally and the ability for surrogate consent and for that consent model to 
be integrated within database infrastructures that enable secondary use of data 
research studies that analysis streams of data collected from sensors in relation to 
patient care is introduced. This is then followed by a comparison of existing 
consent models that are used in research and medical practice. 
 
2.1 Identification of Literature Review  
The literature review followed a three-phase approach as shown in Figure 2:  
 
Figure 2: Literature review method.  
Adapted from (Yao, Chu, & Li, 2010) 
 
 
I) Literature Search, Compilation and Selection 
A search using PubMed, IEEE Xplore Digital Library, JSTOR, ScienceDirect, 




issues of informed consent. First, as it applied generally to secondary use of health 
information for research purposes, and second, more specifically in situations of 
proxy, or surrogate, consent. Search terms included the following, combinations 
and their synonyms: consent (e.g. “proxy consent”, “surrogate consent”), consent 
models, health data, identifiable data, medical data, patient data, physiological 
data, health records, neonatal research, health research, neonatal intensive care 
(unit), secondary use (e.g. “secondary use of health data”) and privacy. Papers 
were constrained to English publications. No date constraint was applied due to 
the fact that many articles cited seminal literature published during at least the past 
century. 
 
II) Literature Categorization and Literature Review Framework 
Literature was separated into categories at each step of the workflow process 
shown in Figure 3. The focus and key ethical issue of this thesis relates to the need 
for a flexible and longitudinal consent model that can be easily applied. Papers 
discussing the potential benefits and challenges relating to the implementation of 
novel consent models were also identified. 
 
Figure 3: Literature Review framework 
Adapted from (Yao et al., 2010) 
 
III) Literature Analysis, Evaluation and Implications 
The literature review framework was applied to the literature. Categorizing 
topics in the previous step helped to guide identification of issues that may arise 
from the secondary use of patient data. It assisted in limiting the literature being 




or treatment of very young infants, especially those in the NICU environment. 
Suggestions and implications relating to the proposed implementation of consent 
models along with areas of open research were also examined.  
The central themes, issues and concerns identified during this analysis are 
illuminated and discussed in this chapter. 
 
2.2 Secondary use of Medical Data 
 The former Article 29 Working Party (which has since been replaced by the 
European Data Protection Board upon enactment of the General Data Protection 
Regulation [GDPR]) defined personal data as health data when:   
1. The data are inherently/clearly medical data 
2. The data are raw sensor data that can be used by itself or in combination 
with other data to draw a conclusion about the actual health status or health 
risk of a person 
3. Conclusions are drawn about a person’s health status or health risk 
(irrespective of whether these conclusions are accurate, legitimate 
illegitimate, or otherwise adequate or inadequate) 
 (Article 29 Data Protection Working Party, 2015) 
 
When raw data should be considered health data is also a matter of scale: a 
pedometer tracking and storing how many steps one has taken for a few days may 
not be “health data” but the combination of several years' worth of extensive 
quantified-self records of an individual (e.g. tracking sleep and exercise habits, 
detailed records of diet, and other vital statistics) will be considered health data. In 
this latter case, the conclusions and inferences, and the raw data will be 
considered health data (Article 29 Data Protection Working Party, 2015; Covington 
& Burling LLP, 2015). 
A category of information which is uniformly considered as health data is the 
category of medical data. Health data (or all data pertaining to the health status of 
a data subject) is a broader term than the term “medical” (Article 29 Data Protection 




care for the primary use of informing the subject’s immediate and ongoing medical 
care (Sandhu et al., 2012). This includes all data related to patient contact, their 
diagnosis and/or treatment, as well as any related information on diseases, 
disabilities, medical history and clinical treatment that are generated within the 
healthcare context.  
When that data is used for a purpose beyond or unrelated to the original care 
event, this is termed secondary use. Secondary use includes activities such as 
research, analysis, quality and safety measurement, accounting and billing, 
provider accreditation and numerous other non-commercial and commercial 
activities research and data mining by advertising companies to increase and 
target pharmaceutical sales (Safran et al., 2007). Personal health data used for 
many of these secondary purposes plays an essential role in expanding knowledge 
and understanding health care and service delivery via knowledge translation.  
The Canadian Institutes of Health Research (CIHR) defines knowledge 
translation as “a dynamic and iterative process that includes synthesis, 
dissemination, exchange, and ethically sound application of knowledge to improve 
the health of Canadians, provide more effective health services and products, and 
strengthen the healthcare system” (Graham, 2012). The following clinical 
knowledge translation life cycle (Figure 4) demonstrates how aggregated patient 
personal health data is translated into patient health information (PHI) when the 
health data is given context. Once a problem is defined, the health information can 
be analyzed to produce knowledge related to the problem. Decisions such as 
treatment options are made based on available information. The outcomes of the 
decision(s) made are then assessed and evaluated and the cycle repeats itself. 
The clinical knowledge translation life cycle is depicted as a continuous life cycle 
as improvements are made to current understanding of medical conditions and 





Figure 4: Clinical knowledge translation life cycle 
                           Adapted from (Deeny & Steventon, 2015; Foley & Fairmichael, 2015) 
 
 Increased adoption of electronic health records (EHR) and health 
information systems (HIS) has also increased the availability and accessibility of 
PHI in electronic form (Grande, Mitra, Shah, Wan, & Asch, 2014; Jones, Shipman, 
Plaut, & Selden, 2010). PHI has substantial value in a wide range of secondary 
uses (Grande et al., 2014; Weiskopf et al., 2013). Some secondary uses such as 
disease progression research are utilitarian in nature, while others are potentially 
undesirable. Examples of the latter include where EHRs, some still including 
personal identifiers, have been made available to law enforcement for undisclosed 
and warrantless use in immigration and drug investigations, or debt collectors and 
credit reporting agencies being provided treatment records for medical 
indebtedness, and more recently where hackers and criminals have created false 
identities based on the contents of stolen EHRs for use in medical billing and 




Many accept utilitarian secondary use of EHR in research that benefits the 
community (Hill, Turner, Martin, & Donovan, 2013). Ploug and Holm (2017) found 
that very few people do not want their data used for any kind of research – in fact, 
many are willing to permit their data be used without specific consent, in 
particularly for public research. However, the majority consistently across data and 
research types want some control over the use of their data (Ploug & Holm, 2017). 
Another 2009 study examined the consent preferences of a group of breast cancer 
survivors (Vermeulen et al., 2009). 70% of respondents said they would appreciate 
the opportunity to decide whether they wish to participate in research. Genetic 
research was also perceived to be valuable and unproblematic and, similar to 
many other consent-related studies, that adult respondents support research that 
could benefit future patients in some way (Vermeulen et al., 2009). A dichotomy 
exists between what the general public considers acceptable research deserving 
of altruistic data sharing, and less acceptable research conducted by commercial 
enterprise (Hill et al., 2013; Vermeulen et al., 2009; Willison et al., 2007). Rather 
than objecting to issues arising from the ethics or study design, the key division is 
seen to arise when the commercial entity profits from the research, patenting the 
knowledge gained and limiting its availability for wider use (Hill et al., 2013; 
Vermeulen et al., 2009). Patients generally disapproved and felt greater 
restrictions should apply where their health information was to be used for 
commercial research (Hill et al., 2013), believing that profit motivation was contrary 
to the common good (Vermeulen et al., 2009). With regard to the secondary use 
of their data for commercial research and international research in comparison to 
public research, approximately twice as many people want to be approached for 
specific consent (Ploug & Holm, 2017). University researchers often exist across 
a spectrum where acceptability of their research depends on the funding source 
and level of control that funder may exert over the research conduct, results and 
any eventual publication (Angell, 2005; Goldacre, 2014; Hill et al., 2013; Mirowski 
& Van Horn, 2005). 
When health data custodians receive a request to disclose individual-level 




considered to be personal information or not. Should the data be considered 
personal information, obtaining patient consent may be necessary for disclosure. 
Alternatively, it may be necessary to de-identify or anonymize the data (El Emam, 
2010). As a result, there is substantive evidence that explicit consent for secondary 
use of personal health data is required.  
 
2.3 Public Perspectives Regarding Secondary Use of Medical Data 
It is crucial to understand the public opinion of consenting in order to propose 
an improved consent model that promotes flexibility and longitudinal consent with 
regards to the secondary use of physiological data. Heath (2012) conducted a 
survey examining the Australian and Canadian public perspectives regarding 
secondary use of medical data. Heath noted that there are infinite combinations of 
citizens with fluctuating levels of ‘interest’ and ‘capacity’ when it comes to their 
engagement with secondary use of their medical data and privacy related matters. 
The survey examined public opinion concerning privacy aspects surrounding the 
secondary use of medical data. It was found that citizens have diverse concerns 
and expectations regarding privacy. It was observed that respondents of the 
survey can be classified into four broad groups of people described below. Thus, 
Heath (2012) proposed a Privacy Framework that conceptualizes the different 
levels of consumer engagement with each group exhibiting different expectations 
on all matters related to the secondary use of their medical data.  
The aforementioned four broad groups were assigned with levels, ranging 
from levels 0-3 as shown in the consumer engagement diagram in Figure 5. Each 
of these groups exhibit different expectations on all matters related to the 
secondary use of their medical data (Heath, 2012). The first group (Level 0) 
involves persons with low or minimal capacity when it comes to engaging in making 
decisions regarding the secondary use of their medical data. The second group 
(Level 1) includes individuals who have sufficient capacity to participate in 
secondary matters but low levels of interest in becoming engaged. Over time, there 
may be people who develop an increased interest in secondary use of their data, 




may be due to a diagnosis of a medical condition in an immediate family member 
or result from the lingering effect of media reports, such as resale of medical data 
for commercial purposes. In the first case, a family member’s interest level with 
regards to the secondary use of data may rise should there be a chance to 
participate in research related to a medical condition that their family member is 
diagnosed with, whereas in the second scenario, further interest arises as the 
individual tries to protect their medical data from commercial secondary uses. The 
fourth and final group (Level 3) consist of citizens who have both the capacity and 
interest in secondary use matters enabling them to fully be involved in the decision-




Figure 5: Consumer engagement for secondary use of medical data  
(Heath, 2012) 
 
These conceptual groups can be static or dynamic, depending on the ability 
and capacity of the individual making the decision regarding the secondary use of 
data. A capable individual may willingly choose to join the Level 0 group in which 
limited opportunities would be available for consumer engagement in secondary 




regarding their levels of engagement, it would not matter how much interest they 
may express with regards to secondary use matters, as they are unable to make 
the fundamental decisions. Even if they had a desire to join the Level 3 group, the 
Privacy Framework would theoretically limit their engagement to Level 0 (Heath, 
2012). 
The healthcare consumer’s capacity to engage determines their engagement 
levels which is associated with an interest level, which in turn also determines 
one’s consent notification preference when it comes to the secondary use of their 
medical data. Level 1 provides an individual consumer with an opportunity to have 
some input into how their data is used for secondary use at a broad level. At this 
level, the consent is not meant to be at a project specific level but simply a broad 
“yes” or “no” when it comes to the use of their medical data for any kind of 
secondary activities. Should an individual choose to decline consent, then their 
medical data should not be utilized for any secondary purposes. Level 2 is for those 
consumers who wish to be more engaged in the research contribution process by 
allowing them to provide project specific consent, such as choosing if they wish for 
their data to be available for commercial and/or non-commercial. For consumers 
who voluntarily choose to allow themselves to be identified and available for 
contact for future secondary use matters should they meet a project’s inclusion 
criteria, belong to Level 3. It is intended for an individual’s consent preference to 
be stored with their electronic medical record (EMR) (Heath, 2012). 
In a proof of concept study that examines the use of an electronic 
implementation of a Meta Consent (MC) model via the use of a smartphone 
application in Danish adult citizens where they had the ability to choose their 
consent preferences for future secondary research use of health data, it was found 
that the participants should be offered the opportunity to make MC choices given 
the significantly different consent preferences (Ploug & Holm, 2017). The study 
found that the majority of people consistently across data and research types want 
some control over the use of their data. When it came to the secondary use of their 




research, approximately twice as many want to be approached for specific consent 
(Ploug & Holm, 2017). 
 
2.4 Physiological Data in Research 
There is increased interest in the analysis of physiological data, particularly 
in real-time (Sahoo et al., 2014). Medical devices that continuously monitor some 
aspect of the patient represent the largest single sources of physiological datasets 
(Herland, Khoshgoftaar, & Wald, 2014; McGregor, 2013). These datasets may 
record many hundreds or even thousands of data points per minute (McGregor, 
2013). It is already possible to capture electrocardiograms (ECGs), 
electroencephalograms (EEGs) from the scalp and implantable intracranial 
electrodes, and pulse oximetry (SpO2) from medical devices (Sahoo et al., 2014). 
Multiple physiological variables can be computed from a single monitoring device, 
such as when the heart rate (HR), heart rate variability (HRV), respiration rate (RR) 
and chest impedance is recorded from the same ECG signal (McGregor, 2013; 
Pinsky & Dubrawski, 2014).  
Predictive monitoring involves analysis of physiological data to detect 
patterns associated with critical illnesses (Fairchild, 2013). Use of physiological 
data for early and reliable detection has been demonstrated in neonatal 
populations for late onset neonatal sepsis (McGregor et al., 2012), pneumothorax 
(McIntosh, 2000), intraventricular haemorrhage (Fabres, Carlo, Phillips, Howard, 
& Ambalavanan, 2007; Tuzcu, Nas, Ulusar, Ugur, & Kaiser, 2009) and 
periventricular leukomalacia (Shankaran, Langer, Kazzi, Laptook, & Walsh, 2006). 
While healthcare professionals regularly consider physiological variables when 
making diagnostic decisions, at times this has become a routine activity in the 
absence of complete comprehension of their determinants and associations 
relating to the pathophysiology of many conditions. The fact that these variables 
may result from the interaction of numerous complicated and interrelated 
processes is sometimes overlooked, albeit unintentionally. Secondary use 
research using physiological data could investigate and deliver ways to improve 




understanding of disease progression. While progression of research in the 
analysis of physiological data through secondary use of health data has great 
potential to improve health outcomes, medical data such as physiological data may 
reveal more about the source individual than intended by both the consenter (i.e. 
the patient or their proxy consenter) and the researcher(s).  
 
2.5 Big Data Driven Clinical Decision Support Using Physiological Data 
One of the primary contributors of Big Data in health care is the result of 
increased adoption of electronic health records (EHRs) (Murdoch & Detsky, 2013). 
Majority of EHRs capture quantitative data (e.g. laboratory values), qualitative data 
(e.g. text-based documents) as well as transactional data (e.g. documentation of 
medication delivery) (Murdoch & Detsky, 2013). Another contributor of Big Data in 
healthcare, comes from medical devices that continuously intake new data for 
purposes of monitoring a patient’s current health status in real-time (Herland et al., 
2014). The majority of the collected data contributes to a patient’s diagnosis, 
prognosis and treatment based on a healthcare professional’s observations and 
interpretation of the data available (Cios & Moore, 2002). 
The use of Big Data for predictive modelling for real-time clinical decision 
making is increasingly recognized as an approach to achieve what the Institute for 
Healthcare Improvement (IHI) refers to as the Triple Aim – namely improving 
outcomes, enhancing patients’ experiences and reducing health care costs 
(Amarasingham, Patzer, Huesch, Nguyen, & Xie, 2014; Institute for Healthcare 
Improvement, n.d.). Furthermore, the use of Big Data and its associated 
technologies can support the development of preventative care and personalized 
medicine (Murdoch & Detsky, 2013; Sahoo et al., 2014)); empower patients by 
delivering information directly to them, thus encouraging them to play an active 
role in their own health care (Murdoch & Detsky, 2013); and contribute to 
knowledge dissemination that help guide best practices within the literature and/or 
prevent information overload. To solve this issue, data from the EHR can be 
analyzed and the derived information can be used to design a dashboard to enable 




support such that suitable treatment can be delivered to patients especially those 
living with multiple, complicated and chronic health conditions (Murdoch & Detsky, 
2013). Six practical uses of predictive systems that have the greatest opportunities 
to reduce healthcare costs via the use of Big Data include dealing with high-risk 
and high-cost patients (along with the identification of low-risk patients), 
readmissions, triage, decomposition, adverse events and treatment optimization 
for diseases that affect multiple organ systems (e.g. chronic and/or systemic 
conditions) which are the costliest conditions to manage (Bates, Saria, Ohno-
Machado, Shah, & Escobar, 2014). 
Akin to the concept of business intelligence, which results from the prompt 
interpretation of large volumes of data for actionable information, there is a growing 
necessity for the health care sector to adopt a similar model of “health care 
intelligence” in real-time (Sahoo et al., 2014) as one of the limitations impacting 
the effectiveness and efficiency of healthcare analytics is dependent on the time 
required to deliver predictions to health care providers and enable action (Bates et 
al., 2014). In comparison to traditional (clinical) decision support tools which relies 
exclusively on the use of rule-based decision trees, taking the Big Data approach 
means that the predictions and suggestions that contribute to clinical decisions are 
made from real-time data analysis (Murdoch & Detsky, 2013). Simply put, the 
analysis of Big Data will contribute to what the Institute of Medicine (IOM) refers to 
as a “learning health system” where the healthcare sector continuously strives to 
improve on its present-day practices and adopting new approaches such that 
quality care is delivered at lower costs (Adler-Milstein & Jha, 2013). A key 
component of this learning is the discovery of new knowledge via the secondary 
use of health Big Data. It is paramount that patient consent is tied with this 
knowledge discovery task.  
 
2.6 Identifiability of Health Data 
PHI datasets consist of information that can be categorized as direct 
identifiers and indirect identifiers (or quasi-identifiers). Direct identifiers are those 




Indirect identifiers are those fields that can be used to infer the source patient, 
including dates, locations, and socio-economic information. It is possible for the 
source patient to be re-identified from either type, or a combination of both (El 
Emam, 2010). Quasi-identifiers are data elements in individual-specific data that 
in combination associate uniquely, or almost uniquely, to that individual and can 
therefore directly or indirectly re-identify the specific source individual (El Emam, 
2010). Even where other direct patient identifiers (e.g. name and street address) 
were removed, anonymized pharmaceutical marketing data can re-identify the 
source individual using a relatively small number of innocuous demographics such 
as a postal code and the patient’s age (Sweeney, 2000). 
Advantages can arise from the use of patient data for health research 
purposes, however the secondary use of physiological data for research comes 
with privacy and confidentiality concerns relating to the potential biometric 
exposure and identifiability of the individual patient. Biometric data is personal 
information derived from an individual to determine or verify one’s identity 
(International Biometric Group, 2010). Of note within the context of this thesis is 
that physiological biometrics are derived from direct measurements of the 
functioning of systems and organs within the body (International Biometric Group, 
2010). The human body would not normally be considered a transmission source 
of privacy-exposing data (Fairclough, 2014). However, with contemporary 
electronic physiological measurement devices, the conversion of physiological 
metrics into computer recordable data has become a triviality (Fairclough, 2014). 
For example, research studies have demonstrated the ability to identify an 
individual from features in their electrocardiogram (Israel, Irvine, Cheng, 
Wiederhold, & Wiederhold, 2005). 
Heath (2012) conducted a survey examining the Australian and Canadian 
public perspectives regarding secondary use of medical data. Almost all 
respondents (n=90.9%) either agreed or strongly agreed that they would be more 
likely to consent reuse of their information for research purposes if they could be 




repeatedly been drawn into question, further research into privacy-protecting 
techniques for PHI data disclosure is needed (El Emam et al., 2011; Ohm, 2010).  
While physiological data has the potential to unintentionally reveal otherwise 
unknown information about an individual, many are still willing to consent use of 
physiological data, including those captured from their neonates, as a resource for 
advancement of health research (McGregor, Heath, & Choi, 2015). The continuing 
issue of identifiability from PHI and biometric data motivates a need to provide 
participants with options, including an ability to adjust or withdraw consent for 
further secondary use at a later date. Consequently, the incorporation of the 
functionalities to allow for flexibility and change of consent longitudinally is 
important within a consent model. 
 
2.7 The History of Informed Consent 
Healthcare professionals are concerned with adherence to ethical duties to 
inform the patient regarding their condition, status and treatment options. Their aim 
is to seek, and only perform, those interventions that the patient explicitly consents 
to (Beauchamp, 2011). This patient-empowerment approach is in response to 
events during the second world war and resulting Nuremberg trials, and more 
recent litigations in the United States of America and elsewhere. Previously, 
doctors were more concerned with avoiding disclosures that could potentially harm 
or upset patients, giving less consideration to patient’s rights and whether there 
was approval for treatment the doctor intended to perform (Beauchamp, 2011). 
Valid informed consent consists of four elements: competence, 
understanding, voluntariness and information. The goal is to provide a mentally 
competent adult (defined as an individual who is of sufficient age and mental 
capacity) with sufficient information, in an appropriate language such that he or 
she can make a free, voluntary and adequately informed decision regarding 
potential participation in a research study as a research subject (Allmark & Mason, 
2006; Burgess et al., 2003; Canadian Institutes of Health Research, 2005; Mason, 
1997; McKechnie & Gill, 2006; Nijhawan et al., 2013; Oberle, Singhal, Huber, & 




manipulation (Canadian Institutes of Health Research, Natural Sciences and 
Engineering Research Council of Canada, & Social Sciences and Humanities 
Research Council, 2018). Research subjects can withdraw their consent at any 
time and in the event they do, they can also request for the withdrawal of their data 
or human biological materials (Canadian Institutes of Health Research et al., 2018) 
Informed consent does not require perfect or complete understanding. 
Rather, informed consent is based on the idea that autonomous decisions reflect 
what an individual intends to do, which is only possible if the individual adequately 
comprehends the relevant information (Pedroni & Pimple, 2001). When it comes 
to consent to participate in research, the information provided must accurately 
reflect the study’s purpose, methods, risks, benefits, any alternative options to the 
research and his or her right to choose (Nijhawan et al., 2013). 
Meta consent (MC) is a new flexible consent model proposed by the authors 
such that it provides individuals the ability to choose how and when they wish to 
provide consent for future secondary use of biological samples or health 
information collected in the past or those that will be collected in the future.  
 
2.8 Value of Informed Consent  
While Ploug and Holm (2015) identify broad consent as its own category in 
Table 3, they do not list blanket consent (and refusal) as its own distinct category; 
rather they suggest it as an option under the MC model. The difference between 
broad and blanket consent should be clarified. Wendler (2013) provides a 
clarification of the definition for the two terms based on the collection and use of 
human biological samples. Broad consent refers to a process by which individuals 
donate their samples for a broad range of future studies, subject to specified 
restrictions. An example of a broad consent restriction may be that if certain types 
of research are known to conflict with the participant’s fundamental values, this 
could be precluded at the point of initial consent (Wendler, 2013). Blanket consent 
means that an individual’s collected sample would be used without further consent 
or restrictions. Patients provide consent once and entrust researchers and ethics 




& Daar, 2003; Pentz, Billot, & Wendler, 2006; Ploug & Holm, 2015c; Wendler, 
2006). Much concern and debate has been raised as to whether or not broad or 
blanket consent should be considered valid informed consent (Caulfield, 2002; 
Caulfield et al., 2003; Ploug & Holm, 2015c; Sheehan, 2011). This is especially the 
case with blanket consents as they are necessarily vague and thus are too general 
to have much legal weight. They do not enable participants to act meaningfully in 
their continuing interest or control their health information  (Caulfield, 2002; 
Caulfield et al., 2003). Kaye et al. (2015) also note that the expression of individual 
autonomy is not static and involves making choices and decisions (e.g. the 
decision to participate in research) over the course of one’s lifetime. 
 Many suggest that it is always appropriate to obtain consent, even if it is 
done in the most general manner (e.g. via blanket consent) because even in the 
event an individual makes the decision to provide their consent, they may 
nonetheless prefer to be asked for their permission (Kass et al., 2003). Studies 
focusing on adult research subjects who are capable of consenting for themselves 
revealed that they feel respected and valued by being asked for consent and 
consider the opportunity to actually give consent of secondary importance 
(Vermeulen et al., 2009). All of these factors once again emphasize the importance 
of the consent process and the need for a consent model that is flexible and allows 
for consent preferences to be changed in the future. In the event a patient is unable 
to consent, surrogate and substitute decision makers both appreciate being asked 
for consent and having the ability to consent on behalf of the patient. 
 
2.9 Proxy Consent  
The informed consent process is readily actionable when it comes to 
engaging with an alert and competent adult. It is generally assumed that adults 
have decision-making capacity until proven otherwise. However, obtaining 
informed consent presents significant ethical and legal difficulties where certain 
groups of people are concerned; this includes minors (i.e. individuals under the 
age of eighteen), those who are mentally disabled, those of limited capacity, and 




during which they have been rendered unable to consent for themselves 
(Canadian Paediatric Society, 2004; Committee on Bioethics, 1995; Cooke, 2005; 
Mason, 1997; Nijhawan et al., 2013). With these groups, a proxy is required to 
make decisions on their behalf (Canadian Paediatric Society, 2004).  
In most situations, a family member or a loved one acts as the proxy decision 
maker. There are two proxy types: substitute and surrogate. Substitute decision 
makers are individuals who know the patient well enough to have already 
discussed their wishes for care in such situations with them (Canadian Paediatric 
Society, 2004). The substitute decision maker is an adult, legally able and 
competent to consent on the patient’s behalf. Depending on the circumstances, 
this adult may be designated through enduring power of attorney, or via a living 
will (Richards, 1993). A substitute decision maker’s role is to promote the patient’s 
expressed wishes (Canadian Paediatric Society, 2004). In other situations, the 
proxy consenter may not know what the patient would want done, but are tasked 
with the responsibility of acting (i.e. making decisions) in their best interests, in 
which case they become a surrogate decision maker (SDM) (Canadian Paediatric 
Society, 2004). 
When the situation concerns a minor, parents generally act as SDMs, unless 
the child or adolescent (i.e. mature minor) demonstrates the decision-making 
capacity and is accepted to have the capacity to express their own wishes 
(Canadian Paediatric Society, 2004). Factors affecting surrogate parental 
decision-making in the NICU environment are discussed later in chapter 3. 
This demonstrates a clear need for a consent model to enable consent to be 
provided by a substitute or surrogate consenter and in so doing providing the ability 
to record the details of the person providing consent. Within this research whether 
the concept of substitute and or surrogate is reflected in the use of the term 
surrogate though the same functionality supports the notion of a substitute 





2.10 Longitudinal Consent  
A longitudinal study collects information from the same set of research 
subjects at multiple points over time and are often conducted over an extended 
period of time with varying timeframes (Wood et al., 2014). Longitudinal data as 
they provide the opportunity for researchers to study trends throughout individual 
lifetimes or generations. Similarly, longitudinal consent within the context of this 
thesis is used to refer to requesting permission for the secondary use of collected 
data (or samples) over an extended period of time for a research project (or 
projects) with no specified end date while allowing for ongoing dynamic 
engagement during the process.  
It must be considered whether a MC or DC model (the latter as presented by 
Kaye et al. (2015)) could potentially be applied to secondary uses of physiological 
data that can occur several years after the initial data collection. In comparison to 
the DC model, the MC model offers a unique feature that allows an individual to 
choose how they wish to provide consent for future secondary research of health 
data collected in the past, or of data that will be stored in the future (i.e. MC is both 
retrospective and prospective). Conversely, DC would only apply to future use of 
data and samples (Ploug & Holm, 2015a, 2015d). Hence, MC is better suited in a 
situation that calls for a longitudinal and flexible consent model. As the case study 
context for this thesis is based on the NICU, this would be the ideal opportunity to 
set up a MC model, gradually introducing this concept to two population groups: 
parents of the neonate patient, and the neonates themselves when they attain 
adulthood under the assumption they can demonstrate competency. As described 
previously, parents or legal guardians would generally be those providing 
surrogate consent. Thus, the consent model of choice for this thesis is the MC 
model. However, as there is limited literature regarding the MC model and its 
implementation in this manner, the following review regarding IT consent tools is 
drawn from papers that examine the DC model. This is due to the general similarity 
of these two consent models. 
Initially developed in biobanking, DC refers to both a specific project as well 




use of their personal information. It is also an interactive personalized interface 
that provides participants with the ability to choose their engagement levels and 
consent preferences in real time (Kaye et al., 2015).  
The concept and approach serve as the focus of this thesis wherever the 
term DC appears in this thesis. DC is a participant-centered initiative (PCI) that 
places patients and participants in the center of decision making (Kaye et al., 2015; 
Oxford University Innovation, n.d.). Kaye et al. (2015) explicitly note that DC should 
not be seen as a replacement for: 1) existing consent models (e.g. broad consent), 
2) face to face human contact at the initial point of consent, or 3) the discussion 
process regarding re-consent; instead, such models should be seen as “a 
facilitation tool to improve how that consent is obtained, understood and acted 
upon”. 
Longitudinal biobanks have recognized the limitations of one-off static 
consent. They have also recognized that there are often multiple researchers and 
multiple projects, making it challenging if not impossible to obtain informed consent 
for all future secondary uses of collected samples and data. Re-consenting is 
costly in terms of time, effort and resources and it may also be impossible to locate 
individuals, leading to high drop-out rates (Kaye et al., 2015). This is compounded 
by the expectation that research studies are traditionally hypothesis-driven, and 
does not take into consideration hypothesis-free research, where the research 
question(s), purpose, hypothesis, duration, and/or end points of the study may not 
yet be defined (Bates et al., 2014; Kaye et al., 2015). This is the case in ever-
evolving research fields such as data mining studies, that are longitudinal in nature 
(Bates et al., 2014).  
Similar to the acceptance of “patient-centric” approaches in health care in 
recent years, the adoption of “user-centric” approaches have been rapidly gaining 
momentum given the growth in data sharing related activities (e.g. research), 
leading to the development of various participant-centered initiatives (PCIs). PCIs 
are defined as “tools, programs and projects that empower participants to engage 
in the research process and, in many cases, can differentiate between a range of 




Edwards, 2012; Kaye et al., 2012).  While PCIs are each different in their own 
ways, all of them support the idea of placing research participants at the center of 
decision making via the use of an interactive IT interface to promote the idea of 
treating participants as active and equal partners within the research process. This 
approach, based on the principles of empowerment and respect of individuals, 
reflects the transforming mindsets towards privacy and individual involvement 
(Kaye et al., 2012).  
 
2.11 Information Technology Consent Tools 
The use of interactive IT tools for consent have great potential to support 
easy consent interactions over time, enabling personalized, flexible and 
longitudinal engagement. In comparison to traditional paper-based documentation 
of consent, the consent process is no longer “locked in time” and can be configured 
to run on a variety of IT platforms (e.g. website, tablets and mobile phones) (Kaye 
et al., 2015). All aspects of the interface can be customized to an individual’s needs 
and preferences (Kaye et al., 2015). Participants can be provided with the ability 
to consent to new projects or change their consent choices. They can select their 
level of engagement, the types of information and projects they are primarily 
interested in receiving, how they prefer to be contacted and the frequency they 
wish to be contacted (Kaye et al., 2015). All these changes can be performed in 
real-time and individuals can have confidence that any changes in their choices 
will be effective immediately.  
Kaye et al. (2014) provide a case study specific example of the enabling of 
this approach by demonstrating that specific consent provisions travel with a 
participant or donor’s data and samples as they are shared or accessed for 
different purposes. These consent provisions can be electronically and 
cryptographically “wrapped” with the donor’s samples and information (Kaye et al., 
2015). All participant information (including one’s consent preferences) are 
conveniently stored within an accessible interface.  
An IT platform could also enable general research results to be returned to 




acknowledgment for their contribution and involvement or by informing them how 
their samples and information have been used (Kaye et al., 2015). This approach 
encourages better communication and transparency between researchers and 
participants.  
A flexible, multi-level consent model that ties consent data and collected 
study data from consenting individuals (or by proxy consenters) within a research 
database would allow for the aforementioned features of customizability in an initial 
and longitudinal manner and although outside the scope of this thesis, the 
possibility of informing contributors how their samples and information will be used 
in the future.  
While the work of Kaye et al. (2015) demonstrates the potential benefits of 
coupling consent with the study data, they have not provided a systemic approach 
to support multiple studies.  
 
2.12 Comparison of Consent Models 
Many models are available for consenting patients in clinical practice and 
clinical research. Those identified during this work are listed in the furthest left 
column in Appendix A, which provides a brief description as well as advantages 
and disadvantages of the identified consent model. Consent models were found to 
be fundamentally based on the concept of obtaining a one-time broad consent. 
Addressing the research objectives of this thesis required a consent model that 
allows for functionalities of flexible longitudinal surrogate consent, with the ability 
to be coupled with data and employing the use of IT tools. Below, Table 2 provides 








Flexibility   Allow SDM(s) to: 
1) choose their consent preferences 
2) adjust their chosen consent preferences at any time   
Surrogate 
consent 
Neonates are incompetent - parents or legal guardians often  
act as their neonate’s SDMs 
Longitudinal 
consent 
  Allow SDM(s) to: 
1) choose their consent preferences 
2) adjust their chosen consent preferences at any time and  
3) ensure chosen consent preferences take effect immediately 
Coupled with 
data 
Ensure that consent data is coupled with research study data 
(i.e. collected PHI)   
Information 
Technology (IT) 
Enable consent model to be integrated within database 
infrastructures that enable secondary use of data research 
studies that analyze streams of data collected from sensors in 
relation to patient care 
 
Table 2: A table depicting the various functionalities required and their reasons for including the 
functionalities in the proposed consent model 
To identify which existing consent models address the research objectives, 
Appendix A compares the consent models based on their ability to allow for the 
functionalities specified above in Table 2. Appendix A also provides a description 
as well as the advantages and disadvantages of the model, From the left to the 
right columns, the table is read as follows: the consent model name, the model’s 
description, and advantages and disadvantages, with a plus sign (+) indicating the 
advantages while a negative sign (-) indicates a disadvantage of the consent 
model. An “X” in a column that identifies a functionality indicates that functionality 
is met by the specified consent model.    
It is noted that the majority of existing consent models are geared towards 
primary care and may not address the needs of secondary usage of biological and 
genetic samples, or patient data. These consent models are not designed for 
longitudinal engagement and do not provide individuals, specifically proxy 
consenters (e.g. surrogate consenters) with the flexibility to customize their 





Ploug and Holm (2015) classified informed consent models into four broad 
categories shown in Table 3, which includes informed, broad, dynamic and meta 
consent. Of particular interest to this thesis are the dynamic consent (DC) and 
meta consent (MC) models. Meta consent (MC) is a new flexible consent model 
proposed by the authors such that it provides individuals the ability to choose how 
and when they wish to provide consent for future secondary use of biological 
samples or health information collected in the past or those that will be collected 
in the future. The MC model is formally defined as any consent model that allows 
an individual to explicitly express their personal preference for how and when to 
provide consent (i.e. to design future consent requests). Ploug and Holm (2015a, 
2016) note that by allowing an individual to express a preference for how and when 
to provide consent, one can be said to be providing consent on a meta level. 
An individual can choose their preferred consent model, whether broad, dynamic, 
blanket consent or refusal for different types of research (Ploug & Holm, 2015b). 
In the event that a future research study falls under more than one category, the 
most restrictive consent choice would apply (Ploug & Holm, 2015a).  
MC consists of the following six functional elements:   
1) A limited number of categories for designing consent requests  
2) A key for the prioritization of consent requests 
3) A definition of the time for providing MC 
4) A default setting if MC is not provided  
5) A scheme for redesigning MC  
6) A method and infrastructure for requesting and recording MC  
 





Table 3: A brief overview of the focus, use of collected samples and/or data and issues associated with the informed 
consent, broad consent, dynamic consent and meta consent models.  
Information content adapted from: (Canadian Institutes of Health Research, 2005; Kaye et al., 2015; Manson, 2019; 




Focus Use of collected 






Known and disclosed 
use at time of consent 
Additional consents may be 
difficult or impractical 
Broad 
Consent 
All projects of particular 
type  
 
  Not all future uses  
  predictable at time  
  of consent 
Future uses do not constitute 
valid informed consent 
 








Additional consents may 
be difficult or impractical 
Known and disclosed 
use at time of consent 
Not all potential participants 
will connect and opt in 
 
Not practical for research 
using routine clinical data 
 
Every request requires 
description of entire project; 






can select broad or 
dynamic on a case by 
case basis 
 
Retrospective = known, 
prospective = unknown 
Original authors foresee no 
issues as it is their proposed 
model 
 
Others have pointed out that 
it is possible that the costs 
and burdens of such a 
framework may be much 
higher than asking 
participants to reconsent 
 
• Care will need to be taken to 
avoid false positives where 
those who chose broad 
consent are contacted by 
mistake 
•  
• Problem of what to do when 
participants fail to reply 
•  
Administrative systems need 
to be in place to track, and 
accurately respond to, 




Table 4 serves two purposes: first, it provides a comparison of the DC and MC 
models as described by different sources, and second, it evaluates whether the consent 
model meets the functional requirements of this thesis. These include whether it 
possesses elements for longitudinal engagement, flexibility and surrogate consent. These 
requirements are appropriate to the secondary use of physiological data in the NICU 
context: Longitudinal engagement and flexibility features allow the consenter to alter their 
engagement level and consent preferences as circumstances change over a long or 
undefined period of time. Inclusion of surrogate consent is necessary given that the target 
patient group in this case are neonates, who would be unable to express opinions with 












● Participant centred, model: 
information about specific secondary 
use of health data or tissue and a 
request for consent is put to the 
individual via a web-based platform 
● Protects the participant’s autonomy by 
providing information about each new 
data application  
● Makes provision or withholding of 
consent easy and flexible 
● Would be asked for specific consent 
for every new research project in that 
category that uses their data 
● Combines the broad and 
dynamic models, with additional 
options for blanket consent and 
blanket refusal 
● One can choose how they wish to 
provide consent for future 
secondary research of data 
collected in the past or of data 
that will be stored in the future 
(i.e. MC is both retrospective and 
prospective) 
● Individuals can choose the type 
of consent: DC, broad consent, 
blanket consent/refusal for 
different types of research 
DC, MC DC, MC  
Kaye et al. 
(2015) 
● Personalised, communication 
interface to enable greater participant 
engagement in clinical and research 
activities 
● Participant-centred initiative (PCI): 
places patients and research 
participants at the centre of decision 
making 
● Provides an interactive IT interface to 
engage with participants 
● Allows interactions over time; enables 
participants to consent to new 
projects/alter their consent choices in 
real time 
● All aspects of the interface can be 
customized  
● Individuals could provide different 
types of consent depending upon the 
kind of study  




● Participants could choose to consent 
to: a broad range of uses of their 
samples and data, opt to be 
approached on a case-by-case basis, 
set different preferences for different 
types of research (i.e. such 
preferences can be ‘opt ins’ or ‘opt 
outs’),to give a broad consent or can 
tailor their profiles to receive no 
information for specified periods of 
time  
● Allows general research results to be 
returned to participants according to 
their preferences, either as a simple 
‘thank you’ acknowledgment for their 
contribution and involvement or by 
informing them how their samples and 




● A matter of choosing how to be and 
stay informed and provide consent to 
research participation 
● Normally offered within the context of 
a specific project 
● May incorporate broad consent but not 
on the basis of an individual’s 
preference for this type of consent; 
only if “a public engagement strategy 
has identified that people were content 
with consenting to broad types of data” 
● Presents an individual with an 
overview of types of data and types of 
research for which different types of 
consent may be requested 
● Does not introduce consent defaults 
● Does not protect:                                     
§ 1) individual preferences 
§ 2) against the routinization of  
                consent  
§ 3) the ability to conduct research  
● Unlike DC, MC protects an 
individual’s preference for 
participation and an individual’s 
preference for how and when to 
provide consent 
● By providing an individual with an 
overview of different type of 
research and research contexts, 
MC allows the individuals to reflect 
on the consistency of their 
preferences concerning 
participation in research in general. 
DC does not offer such 
possibilities. 
● May limit routinization by allowing 
an individual to limit the number of 
consent requests through broad or 
blanket consent/refusal to 
predefined broad types of research 
and predefined types of research 
context 






    when 1 and 2 are adequately  





● Participant-centric approach 
provides an interface that ensures 
patients can give, review and 
change their consent preferences 
while allowing two-way interactions 
between researchers and 
participants 
    DC  
 
Table 4: Comparison of definitions for dynamic consent and meta consent models by different authors 




Despite differing views of DC as presented by Ploug and Holm (2015) and 
Kaye et al. (2015), Kaye et al. (2015)’s version of DC seems to incorporate 
elements of both Ploug and Holm (2015)’s DC and MC models. In fact, in a later 
publication, Ploug and Holm (2016) openly acknowledges that the Kaye et al. 
(2015)’s DC model is extremely similar to their proposed MC model with regards 
to: 
• The reliance on modern IT (Ploug & Holm, 2016) 
• The underlying concept of providing individuals with a longitudinal consent 
model that provides them with the flexibility to change their consent and 
engagement preferences regarding the future use of their health data and 
samples (Ploug & Holm, 2016) 
• Enable the aforementioned preferences to be communicated to researchers 
(Ploug & Holm, 2016) 
 
There are also visible differences between the two consent models. The initial 
motivation for the development of the two consent models is different. DC is 
“normally offered within the context of a specific project” (Kaye et al., 2015; Ploug 
& Holm, 2015a) and was initially developed to solve consent issues in the 
biobanking field (Kaye et al., 2015; Ploug & Holm, 2016). Its primary focus is on 
the matter of choosing how to be and how to remain informed and provide consent 
to research participation (Ploug & Holm, 2016). In comparison, MC was developed 
with the goal of handling the consent preferences for a whole population for all 
kinds of data and biological samples for many types of research contexts in a 
prospective or retrospective manner (Ploug & Holm, 2015a, 2016). Given that 
medical research is likely to require the involvement whole population datasets in 
the future, it is fundamental that the MC model engage with every single citizen in 
their role as potential participants in big data research (Ploug & Holm, 2016). Due 
to the possibilities of linkage it is also imperative that researchers know if they can 
use a particular piece of data within a dataset that has not yet been previously 
used for research (Ploug & Holm, 2016). This is determined through a definitive 




model enables this as it is designed to allow individuals design future consent 
requests on the basis of predefined types of consent, data, and contexts (Ploug & 
Holm, 2016). In contrast to DC, MC may introduce a default consent setting if 
individuals do not make consent choices themselves (Ploug & Holm, 2016). Unlike 
DC, MC is designed to take into consideration that research may re-use data that 
has been collected at various times, for different purposes and under different 
consent regimes, and is meant to protect: 1) individual preferences, 2) against the 
routinization of consent and 3) the ability to conduct research when 1 and 2 are 
adequately protected (Ploug & Holm, 2015b). Ploug and Holm (2016) point out that 
advocates of DC model could incorporate this meta aspect of the meta consent 
model, and thereby make their model substantially identical to the MC model. But 
unless and until they do so, the two consent models remain distinct (Ploug & Holm, 
2016). Although it is far from obvious that ‘meta choices’ of this kind works in 
practice, Ploug and Holm (2017) later go on to report and analyze the results of a 
proof of concept implementation of MC as a front end application for smartphones 
and tablets to determine whether MC preferences can be successfully elicited in 
the adult Danish population via a smartphone application. Results indicated that 
very few people do not want their data used for any kind of research, and many 
are willing to allow their data be used without specific consent, especially when it 
comes to contributing to public research. The majority of respondents consistently 
across data and research types wanted some control over the use of their data. 
The study also revealed that people have significantly different consent 
preferences, thus emphasizing the requirement for a nuanced consent system 
such as MC (Ploug & Holm, 2017). 
Ploug and Holm (2015) also suggest some valid points as well as practical 
implementation tips regarding their MC model that could also be applicable to the 
DC model. For example, while neither of the models explicitly meet the functionality 
for surrogate consent, they proposed that the MC model be arranged early in life 
which could be achieved by making it mandatory as an individual reaches the age 
of majority (in their jurisdiction), referring to their legal age for decision-making. 




suggested that failure to do so can be managed in different ways, such as via 
reminders from healthcare professionals, or perhaps a broad consent model can 
be applied as a default (Ploug & Holm, 2015a, 2015c). In essence, they also take 
into consideration the concept of proxy consent which the DC model or 
recommendations for its implementation does not explicitly mention. Hence this 
thesis addresses the gap and currently unaddressed needs by proposing a multi-
level participant consent model within a research database that allows surrogate 
consenters the flexibility to modify their consent preferences longitudinally while 
ensuring that consent preference data is linked with the research data within the 
database. 
 
2.13 Conclusions and Implications on Research  
The secondary use of health data, such as real-time analysis of physiological 
data for research purposes requires informed consent. Despite the many available 
consent models that have been proposed, the majority of the traditional models in 
current practice are based on broad consent and are generally meant for a one-
time use of the collected data or sample. The recent introduction of DC and MC 
are proposed as flexible models that may be appropriate for longitudinal research 
with secondary use data as they provide participants with the flexibility to choose 
and adjust their level of engagement and consent preferences via the use of 
interactive web-based IT tools and can be applicable in situations where proxy 
consent such as surrogate consent, is necessary. Although both models offer 
similar features, upon evaluation of both models, the concept of the MC model is 
used as the basis of the consent model for this thesis given its ability to provide 







3. Literature Review – Neonatal Intensive Care Context 
This chapter provides contextual information for the case study context for 
this research, namely that of neonatal intensive care. It begins with an overview to 
the physiological data continuously being generated, followed by a discussion of 
current approaches to, and the need for neonatal research. As parents are often 
the surrogate decision makers (SDMs) on behalf of their neonate, it is also 
important to understand their attitudes towards neonatal research and how this 
impacts their engagement with the consent process and research generally. The 
significance of delayed consent is also examined. The chapter then introduces the 
topics of late onset neonatal sepsis (LONS), a serious condition that can have 
devastating effects on the neonatal population and how heart rate variability (HRV) 
research could assist with providing earlier detection of LONS are provided. To 
emphasize and demonstrate the need for a flexible multi-level participant consent 
model that enables changing consent preferences longitudinally and the ability for 
surrogate consent, the condition will serve as a clinical case study in chapter 4. 
This chapter motivates the need for consent models enabling longitudinal 
consent and consent performed by proxy, specifically parental surrogate consent. 
The chapter concludes with a summation of the functional requirements within a 
consent model that are necessary to incorporate these consent functional 
components. 
 
3.1 The Neonatal Intensive Care Unit Environment 
The NICU provides medical care for premature and ill term infant patients, 
collectively known as neonates. Neonates include newborn infants and infants up 
to twenty-eight days of age inclusive (Ligi, Boubred, Grandvuillemin, & Simeoni, 
2011). This crucial transitional period is characterized by the physiological 
immaturity of many body organs and systems (Ligi et al., 2011). Throughout the 
entire human lifespan, it is also during this period that the infant is at the highest 
risk of dying (World Health Organization, n.d.). It is imperative to improve the 




is generally considered an intensive or critical care unit, that is, a hospital ward 
where the staff to patient ratio is maintained much lower to allow for near one-to-
one care of those with severe or life threatening conditions (Lang, Hodge, Olson, 
Romano, & Kravitz, 2004; McGregor, 2013; Momtahan, Hetu, & Tansley, 1993; 
Rothschild et al., 2005; Tarnow-Mordi, Hau, Warden, & Shearer, 2000).  
Within the NICU, a variety of medical equipment is used to support care of 
the neonate, monitoring vital signs, performing or assisting with breathing, 
maintaining body temperature, or delivering necessary drugs and nutrients to the 
child (Donchin & Seagull, 2002; Make et al., 1998; McGregor, 2013; Momtahan, 
Hetu, & Tansley, 1993). Many of these devices continuously collect physiological 
or other clinical data streams that fluctuate on a second-by-second basis that 
caregivers are ultimately responsible for translating into actionable information 
(Donchin & Seagull, 2002; Make et al., 1998; McGregor, 2013; Momtahan et al., 
1993). These devices produce audible and visual alerts when a measurement 
produced by the neonate breaches that of the devices’ pre-set standardized 
population thresholds, potentially suggesting an abnormality in one’s health 
condition  (McGregor, 2013; Momtahan et al., 1993). Considering that many of 
these physiological and other data streams produce thousands of readings per 
minute per day for a single patient  (McGregor, 2013), the data generated in critical 
care units is considered a Big Data problem. As noted in the introduction chapter, 
there is great potential for these continuous real-time physiological and other data 
streams to provide earlier recognition of the deteriorating patient. However, 
research is required to explore this which requires consent.  
 
3.2 Surrogate Consent 
Research in minors is permitted only if the child is exposed to no more than 
minimal risk and has the opportunity to benefit from the study (Mason, 1997). 
Consent is required regardless of whether a study is assessed as minimal risk, in 
order to preserve patient autonomy. Even data sharing for secondary research has 
potential for privacy and security breaches or incidental findings. Advising the 




consent. Neonates, lacking competency, represent a unique group of research 
subjects (Ballard, Shook, Desai, & Anand, 2004). As they are obviously unable to 
provide consent on behalf of themselves, a surrogate decision maker must decide 
by proxy.  
Since parents/legal guardians are traditionally and legally allowed to provide 
consent for their neonate’s medical care under the assumption that they have their 
neonate’s best interests at heart and act accordingly, it is only appropriate that they 
are typically the ones who researchers and health care professionals turn to when 
they seek permission to enrol the neonate into research (Ballard et al., 2004; 
Burgess et al., 2003; Cooke, 2005; McKechnie & Gill, 2006). Parents are obliged 
to undertake the responsibility of making decisions on behalf of their infant; a 
concept described in the legal domain as surrogate consent (Cohen, Trentalange, 
& Fried, 2015; Flaherty, 2017). However, the proxy consent at best represents 
parental discretion, preferences and family values (Cooke, 2005; Mason, 1997). 
Although pediatric researchers generally agree that parents should act in the role 
of SDM, opinion is divided with some feeling that when emotional investiture and 
other issues are factored in, parents may not actually be the most suitable decision 
maker (Canadian Paediatric Society, 2004; Golec et al., 2004; Oberle et al., 2000). 
Other issues can include: 1) the parental lack of decision-making capacity, 2) 
irresolvable differences between the parents with respect to the minor’s care, 3) 
when parents have evidently relinquished responsibility for the minor, or 4) another 
legal guardian has been appointed (Canadian Paediatric Society, 2004). As a 
result, a consent model needs to enable surrogate consent, even if a parent is not 
the individual consenting.  
 
3.3 Parental Attitudes Towards Neonatal Research 
It has been demonstrated that many parents are very willing to enrol their 
neonate in research studies (Ballard et al., 2004; Stenson et al., 2004) even if it is 
known that there are significant gaps in knowledge about the study (Ballard et al., 




the opportunity (Ballard et al., 2004). This is further supported by a study 
conducted by Morley et al. (2005). 
Parental opinions regarding the enrolment of their premature neonate(s) into 
several research studies in the days following birth were examined via the use of 
a questionnaire. Parents of preterm infants in the NICU who were invited to 
participate in two or more research studies were approached with this survey. 
Amongst the 92 invited participants who completed the questionnaire, 10% 
declined to allow their infants to join any studies. The majority of parents were 
willing to have their infant(s) be enrolled in multiple studies. 78% of these parents 
were willing to give their permission to enrol their infant(s) in two or more than 
studies, 58% willing to consent for three or more studies and 20% were willing to 
have their infant(s) participate in more than ten studies (Morley, Lau, Davis, & 
Morse, 2005). Many parents choose to consent for their neonate’s participation in 
research studies because they are hopeful that it would somehow benefit their 
infant (Ballard et al., 2004) while contributing to the advancement of health 
research. According to findings by Morley et al. (2005), 94% of the parents thought 
that if their baby joined a research study, the care of infants in the future would 
either be “better” or “very much better”. Parental altruism was further demonstrated 
when parents were asked, “Who will benefit from these studies?” in which 91% 
responded that “future babies”, 67% said “researchers”, 25% mentioned “my baby” 
and 2% said “no one”. 
It has been suggested that the above findings may be related to the limited 
parental understanding of risk associated with participation in a study (Harth, 
Johnstone, & Thong, 1992), parents who consent for their newborn’s participation 
may be emotionally vulnerable and socially disadvantaged in comparison to those 
who refuse to consent (Harth et al., 1992), or it could simply be a reflection of 
parents’ trust in physicians and the respect they have for physicians’ opinions 
(Singhal, Oberle, Burgess, & Huber-Okrainec, 2002). A MC model would provide 
parents with the flexibility to review the study information and re-evaluate their 
consent preferences at their convenience and perhaps in a setting away from the 




In terms of who should be the ones consenting, most parents felt that they 
should be the ones consenting (Singhal et al., 2002). In Singhal et al. (2002)’s 
study, it was found that 90.1% of parents of NICU newborns and 91.1% of parents 
of normal newborns respectively believed that ‘‘all forms of research with babies, 
no matter how minor, should be carried out only after parents have given informed 
consent’’. A mere 7.0% of NICU parents and 3.9% of parents of healthy newborns 
felt that, ‘‘doctors should make the decisions about which babies should be in 
research; I do not think the parents should have to make a decision’’. This was 
further supported by Burgess et al. (2003) as they found that 93% of parents in a 
retrospective study and 91% in a prospective study were against the option that a 
doctor rather than the parent should make the decision if a newborn should be 
enrolled into a study. Stenson et al. (2004) found that 83% of parents would be 
‘‘unhappy to forgo the consent process for trials passed by the institutional ethics 
committee’’. Singhal et al. (2002) also found that parents did not want their 
newborn to be enrolled in studies without their consent, even if it was considered 
to be low risk. Such data indicates that parents expect to be asked for consent to 
allow for their infant’s participation in research and do not feel it should be left to 
the discretion of physicians. 
Korotchikova et al. (2010) provides a further perspective supporting the need 
for flexible longitudinal consent when they found that it was most common for 
mothers to be approached for consent alone (76%). However, in situations where 
mothers originally agreed to provide consent, half later chose to withdraw after 
discussion with their husbands/partners (Korotchikova, Boylan, Dempsey, & Ryan, 
2010). The investigation revealed that presence of both parents during the consent 
process in the early postnatal period increases a positive response and makes 
obtaining consent more likely. In a recent European Delphi survey of parent 
representatives and clinicians that sought to establish a consensus between 
parent representatives of neonatal associations and healthcare professionals 
concerning the study information deemed essential by both parties to improve the 
recruitment of neonates into clinical trials, it was found that information should be 




2018). However, clinicians agreed, in both Delphi rounds that information could be 
provided to only one of the parent if the other was not available but emphasized 
that the other parent should be informed as soon as possible. Parent 
representatives disagreed with the suggestion that only one parent could be 
informed (Neyro et al., 2018). Consequently, a flexible consent model that can be 
accessed at a convenient location and time while providing the ability to modify 
one’s consent preferences after making a decision after further consultation with 
trusted individuals.  
Even though many studies found that the majority of parents felt that they 
should be the ones making the final decision with regards to providing consent 
(Singhal et al., 2002; Zupancic, Gillie, Streiner, Watts, & Schmidt, 1997), studies 
have also shown that parents want their infant’s physicians to advise them on study 
enrolment. The influence physicians can have on parents raises the notion of 
shared decision making where physicians generally provide the facts and parents 
supply the value (Golec et al., 2004). Parent representatives of neonatal 
associations and healthcare professionals were also in favour of having a third 
person present during the informed consent process, such as a family member or 
their family doctor (Neyro et al., 2018) but healthcare professionals did not share 
this view (Neyro et al., 2018). Other parents have suggested that that a consultant 
be present during all meetings related to neonatal clinical trial participation 
between parents and clinicians with the amount of consultant support provided 
during the consenting process varying in respect to the type of research to which 
parents are being asked to consent their newborn to (O’Shea, Doran, Ryan, & 
Dempsey, 2018). While shared decision-making appears to be a favourable 
solution in helping to reduce the parental burden while helping to maintain parental 
autonomy and family individuality during a stressful time, in reality it can result in 
more ethical problems (Golec et al., 2004). Over time, parents’ opinions may 
become less dependent on the physician though and results in the need to enable 
changing consent over time.  
A MC model would allow parents to consult their neonate’s healthcare 




discussions and decisions outside of the hospital even if they had previously 
decided regarding enrollment in research. It also allows parents to choose to make 
a decision in the privacy of home without on-the-spot influence from anyone or if 
they prefer, the chance to reach out to other people for support if they so wish, 
such as clergy, neighbors, relatives, (formal) support groups or even contact with 
other families who had had a high-risk infant or a multiple birth (Pinch & Spielman, 
1990). 
   
3.4 Delayed Consent 
Excluding situations of emergency research, in the event that a parent is to 
be approached for consent for more than one non-urgent study, Golec et al. (2004) 
recommended that such requests should be made 48-hour apart although 
McKechnie & Gill (2006) specifically points out that there is an absence of evidence 
to support their recommendation (McKechnie & Gill, 2006). It is possible that Golec 
et al. (2004)’s suggestion of delayed consent may have been based on the results 
of studies by Loue et al. (1996), Bosk (2002) and Kuczewski and Marshall (2002). 
The idea of delayed consent arose from a workshop that took place in Uganda to 
examine the system of bioethical principles governing biomedical research and 
clinical trials conducted in the country. Of importance between Western and 
Ugandan cultural differences was the need to involve family members in the 
decision making and consent process for Ugandan citizens. Participants at the 
workshop suggested a waiting period of 48 hours between the time individuals 
were approached about participation in research and the time they make the 
decision to sign the consent form (Loue, Okello, & Kawuma, 1996). Although Loue 
et al. (1996)’s study is not based on the neonatal context, Golec et al. (2004) 
suggested that the findings regarding the importance of respecting cultural 
influences can be applicable to the multicultural settings of many NICU 
environments. Other researchers such as Bosk (2002) and Kuczewski and 
Marshall (2002) likewise supported the concept of delayed consent. They pointed 
out that some sort of “cooling off” period should be implemented such that one can 




help accommodate cultural norms with regards to family involvement in the 
decision-making process all the while without reducing the importance of respect 
for the individual (Kuczewski & Marshall, 2002). It is noted that the significance of 
the waiting period is even more prominent when language issues are involved 
(Golec et al., 2004).  
The proposed Consent of Infants for Neonatal Secondary-use research 
(CoINS) model in this thesis (based on a MC model) can accommodate these 
suggestions by providing parents with the ability and opportunity to review study 
details and modify their consent preferences at anytime and anywhere, such as 
without the immediate influence of the health care setting if they prefer. By 
accommodating for the surrogate consenter’s needs and preferences may 
strengthen one’s understanding of what they are consenting to thus ensuring better 
informed consent and by providing a sense of control may help increase their 
comfort in permitting the secondary use of their neonate’s data. This in turn may 
lead to an increase in consent for neonatal data to be used for immediate and 
future longitudinal research studies thus benefiting society as a whole. 
 
3.5 Late Onset Neonatal Sepsis 
An estimated 15 million – more than one in ten – neonates are born preterm 
annually and the number continues to increase (March of Dimes, The Partnership 
for Maternal Health, Newborn and Child Health, Save the Children, & World Health 
Organization, 2012; World Health Organization, 2018). Preterm birth is a 
significant cause of long-term loss of human potential amongst survivors (March 
of Dimes et al., 2012). Birth complications resulting from a premature birth is the 
leading cause of neonatal deaths and is also the second cause of mortality after 
pneumonia in children under five years of age, accounting for over one million 
deaths in 2012 (March of Dimes et al., 2012) In addition to preterm birth, infections 
is another major cause of neonatal deaths (World Health Organization, 2019). 
Advancements in neonatal intensive care has contributed to the increased survival 
of premature neonates at lower gestational ages. However, even with access to 




increased risk of facing complications, such as the onset of one or more 
comorbidities of prematurity and the development of multiple conditions 
concurrently or over time following their preterm birth (March of Dimes et al., 2012). 
Premature neonates are more likely to develop severe infections and are at an 
increased risk of dying if they contract an infection.  
Neonatal sepsis is a significant global health concern. It is a major cause of 
morbidity and mortality in the high-risk newborn population admitted to the NICU 
(Griffin et al., 2003; Stoll et al., 1996). The majority of neonates who die from 
neonatal sepsis are preterm (March of Dimes et al., 2012). Considering that many 
of the preterm neonates who survive often face a lifetime of disability such as the 
development of neurodevelopmental functioning impairments, learning disabilities, 
and visual and hearing problems (March of Dimes et al., 2012; World Health 
Organization, 2018), a clinical decision support tool that can also improve 
knowledge could dramatically reduce these implications or at the very least 
improve their quality of life.  
Approximately one in four infants born with a very low birth weight (VLBW) 
(< 1500 g) who survive their first three days of life experience at a minimum of one 
episode of LONS while 25% of infected infants experience multiple episodes, 
ultimately resulting in a greater rate of mortality and longer hospital stay (Stoll et 
al., 1996). A timely and accurate diagnosis and treatment of LONS is crucial for 
improved survival rates and quality of life by decreasing complications and other 
adverse outcomes. In order to improve knowledge and understanding about LONS 
requires the contributions arising from health care research, which in turn requires 
the collection of data for such analysis. Analysis of physiological and clinical data 
has the potential to be used as an early detection tool for patients at risk of 
developing various medical conditions. However, the collection of physiological 
data, such as those stored within the Artemis Cloud could potentially be used as 
identifying information. It would only be respectful and appropriate to ask for 
surrogate consent before collecting, identifying eligible patients and use such data 




LONS, also commonly referred to as simply late-onset sepsis is distinguished 
from early onset (neonatal) sepsis according to the onset of age (Dong & Speer, 
2015). The onset of LONS develops three days (i.e. 72 hours) after birth (Dong & 
Speer, 2015; Griffin et al., 2003) at which point it is considered appropriate to 
differentiate LONS from EONS based on the causative pathogens (Dong & Speer, 
2015). It has been noted that the incidence of LONS is inversely associated with 
birth weight (Dong & Speer, 2015) and gestational age (GA) with the incidence of 
infection increasing with decreasing birth weight and GA (Stoll et al., 1996). This 
signifies that immaturity is a great risk factor. Other risk factors for LONS include 
the long-term use of invasive interventions (e.g. mechanical intervention and 
intravascular catheterization), failure of early enteral with breast milk, a prolonged 
duration of parenteral nutrition, hospitalization, surgery and underlying 
cardiovascular and respiratory diseases (Dong & Speer, 2015; Stoll et al., 1996), 
all of which are likely possibilities for preterm and/or VLBW neonates admitted to 
the NICU. 
Whilst the advancement of medicine, medical knowledge and technology 
have led to improved survival of preterm infants (i.e. <37 weeks gestation), in 
particular those who were born with a VLBW, the incidence of LONS has also 
increased in parallel, indicating that the postnatal nosocomial or community 
environment (i.e. hospitalization) and life-sustaining medical devices play a role in 
the pathogenesis of the condition (Cohen-Wolkowiez et al., 2009; Dong & Speer, 
2015). 
Early detection of LONS is difficult due to nonspecific and inconspicuous 
clinical signs (Dong & Speer, 2015). Neonates with sepsis are often detected when 
they are seriously ill. This not only increases morbidity and mortality rates, but also 
reduces the opportunity for a timely and complete recovery with antibiotic therapy 
(Griffin et al., 2003). To date, a blood culture remains as the “gold standard” 
diagnostic test for neonatal sepsis (Meem et al., 2011). However this method is 
not ideal as it is time-consuming and unreliable as it is prone to producing false 
positive and negative results due to the difficulty in determining between a true 




accurate diagnosis and treatment of LONS is crucial for improved survival rates 
and quality of life by decreasing complications and other adverse outcomes.  
 
3.6 Background on Heart Rate Variability Research  
Monitoring of physiological data have shown promise as a potential 
diagnostic tool. Heart rate variability (HRV) is defined as the oscillation in the 
interval between consecutive heart beats (Task Force of the European Society of 
Cardiology the North American Society of Pacing Electrophysiology, 1996). It has 
been observed that abnormal HRV and transient HR decelerations were present 
in some neonates 12 to 24 hours before a clinical diagnosis of sepsis is confirmed 
(Griffin & Moorman, 2001). This phenomenon is attributed to the likely 
consequence of a systematic inflammatory response syndrome, partially mediated 
by inflammatory cytokines (Fairchild, 2013; Griffin et al., 2003). However, that work 
does not take into account that other conditions and situations can result in 
reduced HRV (McGregor et al., 2012). Consequently, many early detections of 
LONS approaches are prone to reporting false positives.  
For example, study results have revealed that the majority of raised HRV 
actually occurred in patients without bloodstream infection (BSI), whereas patients 
with BSI seldom experienced elevations implying that heart rate characteristic 
(HRC) score is neither very sensitive nor very specific in its ability to for BSI 
(Coggins et al., 2016). Thus at this point in time the predictive value of HRV 
monitoring in clinical practice remains undetermined. The results also suggest that 
more than just HRV behaviours should be analyzed when attempting to rely on 
physiological indications rather than physical signs for an earlier diagnosis of 
LONS.  
de Beer et al. (2004) have confirmed that the administration of atropine, a 
muscarinic receptor caused large variations in HRV (de Beer et al., 2004). Loforte 
et al. (2006) examined HRV and the relationship between the heart’s RR-wave 
intervals and the spontaneous respiration in a selected population of ill premature 
infants. It was discovered that lower relationship values were strongly correlated 




respiration relationships could be a potential indicator of infection in premature 
newborns (Loforte, Carrault, Mainardi, & Beuche, 2006). McGregor et al. (2012) 
discovered that the dependence on low HRV alone was limited in helping to 
differentiate between patients who developed LONS from patients who had low 
HRV due to confounding factors such as surgery and/or the use of narcotics or 
other medications. As a result, further clinical retrospective research studies are 
required.  
 
3.7 Summary and Implications on Research 
This chapter has presented an appraisal of various consent issues and 
factors that affect the parental consent process with respect to neonatal research 
performed within the NICU settings. Given that parents often act as their neonate’s 
surrogate decision makers during this challenging time, there is a need to support 
changing proxy consent over time. This motivated the first and second research 
questions: Specifically, a new approach to informed consent is required. It is 
proposed that a consent model that enables flexible, longitudinal and surrogate 
consent would be beneficial to parents. To enable such functionalities requires a 
consent model that can couple consent data with study data within an IT platform 
and be integrated within a systematic platform that can support multiple research 




4. Artemis: A Big Data based Health Analytics for Clinical 
Decision Support and Clinical Research 
This chapter introduces Artemis, a Big Data based Health Analytics platform 
that supports the analysis of high-speed physiological data in real-time to support 
clinical decision support and enable clinical research. The Artemis platform is 
relevant to this thesis as the infant consent model proposed would guide the use 
of data via the Artemis system. At present the platform does not have a consent 
mechanism. 
Artemis is a high frequency, multisource, real time, online health analytics 
platform developed through a collaboration between the University of Ontario 
Institute of Technology (Ontario Tech University) and the IBM T.J Watson 
Research Center (Blount et al., 2010; McGregor, 2017). It is a Big Data platform 
that allows for concurrent multi-patient, multi-diagnosis and multi-stream temporal 
analysis in real-time for purposes of clinical management and research (Blount et 
al., 2010; McGregor, 2013).  
Artemis was named after the Greek goddess of childbearing (Blount et al., 
2010) (Blount et al., 2010; McGregor, 2017). The platform obtains high frequency 
physiological data from neonatal monitors that are located at the infant’s bedside. 
Along with the necessary clinical information, physiological data collected include 
electrocardiogram (ECG), derived signals from the ECG including the heart rate 
(HR), respiratory rate (RR) and respiratory impedance for purposes of breath 
detection. Other signals captured provide information such as blood pressure (i.e. 
diastolic, systolic and mean blood pressure) together with pulse wave 
plethysmography, blood oxygen saturation (SPO2), transcutaneous oxygen and 
carbon dioxide (CO2) measurements when such data is available. The information 
can be simultaneously processed and returned in real-time or stored for later 
analysis and research (McGregor, 2013, 2017; Pugh & McGregor, n.d.).  
 
4.1 Technical Architecture  
The Artemis platform is composed of five different components. This consists 




Extraction and 5) redeployment components as shown in Figure 6. Along with 
pertinent clinical information, physiological data streams are continuously collected 
from medical devices, which are then inputted into the data acquisition component 
of the platform. From the Data Acquisition component, the data is then sent to the 
Online Analysis component where IBM’s InfoSphere middleware system is used 
to process the data in real-time. In conjunction with the newly generated analytics, 
the raw data is stored in the data persistency component of the platform. For 
clinical research purposes, the Knowledge Extraction component performs the 
task of data mining (DM) on the data based on the medical condition of interest.  
 
 
Figure 6: The Artemis platform  
(McGregor, 2013) 
 
4.2 Retrospective Clinical Research Using Artemis  
Examples of neonatal research using Artemis include late onset neonatal 
sepsis (LONS) (McGregor, Catley, Padbury, & James, 2013), apnoea of 
prematurity (Thommandram et al., 2013; Thommandram et al., 2014), anemia of 
prematurity (Pugh, Ng, McGregor, Belik, & James, 2013), premature infant pain 




Although Artemis implementations currently have no influence in the clinical 
setting, by comparing the analytical results that are gathered in the platform with 
current treatment practices, new patterns in real-time physiological data can be 
identified ultimately contributing to the goal of enabling earlier detection and 
prevention of various health conditions before clinical symptoms are visible 
(McGregor, 2013).  
 
4.3 Implementation Hospitals 
The Artemis platform has been implemented to support clinical research 
studies within NICUs at various hospitals. Inclusion of the consent model proposed 
in this thesis as a key component of the Artemis platform implementation would 
strengthen the existing approach through inclusion of surrogate consent. Artemis 
was initially deployed at The Hospital for Sick Children (SickKids) in 2009 for a pilot 
case study regarding late onset neonatal sepsis (LONS) (McGregor, 2017; Pugh 
& McGregor, n.d.). In that deployment, a waiver of consent was granted by REB 
at SickKids. Following the successful Artemis implementation at SickKids, Artemis 
Cloud, a newer cloud computing-based version of Artemis was deployed within 
NICUs at the Women and Infants Hospital of Rhode Island (WIHRI) and the 
Children’s Hospital of Fudan University. Within that deployment, Artemis was a 
sub-study of another study where consent for the primary and sub-study were 
obtained. However, the consent data and study data were not located 
electronically together. More recently was the implementation of the expanded 
Artemis Cloud at the NICUs at McMaster Children’s Hospital (MCH) which will 
allow for high frequency data to be used in real time for analysis at much higher 
speeds than its predecessors (McGregor, 2017; Pugh & McGregor, n.d.). The 
expansion of Artemis Cloud platform provides the ability to service multiple 
healthcare facilities (Khazaei, Mench-Bressan, McGregor, & Pugh, 2015).  
 
4.4 Service Based Multidimensional Temporal Data Mining 
The Data Persistency and Knowledge Extraction components of Artemis are 




(STDMn0) Framework that represent a system, method and computer program 
proposed by McGregor to support multi-dimensional temporal analysis (TA) and 
data mining (DM) (McGregor, 2013; McGregor et al., 2011, 2012). The main focus 
of the STDMn0 framework is to bridge the gap between clinical management and 
clinical research by facilitating the secondary use of data collected from various 
medical monitoring devices. Through the use of DM in physiological data streams, 
STDMn0 enables the identification of previously unknown pathologies by 
supporting the discovery of patterns within physiological data streams that exist 
prior to a clinical condition under investigation (McGregor et al., 2011; McGregor, 
Smith, et al., 2013). 
The original and current STDMn0 architecture is presented in Figure 7.  
 
Figure 7: Original and current STDM n0 database  
(McGregor, Smith, et al., 2013) 
 
The STDMn0 framework is comprised of six layers. As per Figure 7, from the 




Agents, STDMn0 Extensions to CRISP-DM, STDMn0 Agent Tasks, STDMn0 Rules 
Ontology, and STDMn0 Data Management layers (McGregor, Smith, et al., 2013). 
The multi-agent system within the STDMn0 Agents layer drives the overall 
framework, the extended CRISP-DM model layer defines the data mining tasks 
and the STDMn0 Agent Tasks layer are the three main components or layers of the 
STDMn0 framework. The n and 0 in the STDMn0 framework acronym represent the 
extensions enabling support for multiple research studies and null hypothesis 
testing respectively (Dhanoa, 2011).  STDMn0 incorporated the null hypothesis 
approach introduced in Heath (2006) and (Heath, 2006; Heath & McGregor, 2010) 
. 
STDMn0 is built on the foundation of CRISP-DM and enables knowledge 
discovery. The CRoss Industry Standard Process for Data Mining (CRISP-DM) as 
an approach to use for the process of knowledge discovery that is utilized to 
perform clinical research studies is detailed next. The infant consent model 
considered in this thesis would enable the utilization of the STDMn0 with world best 
practice approach to consent. 
 
4.5 Cross Industry Standard Process for Data Mining  
CRoss Industry Standard Process for Data Mining (CRISP-DM) was 
developed in 1996 as a methodology for data mining (DM) processes within the 
knowledge discovery function (Figure 8). CRISP-DM has been established and 
accepted as a cross-industry standard model for DM and knowledge discovery 
(Catley, Smith, McGregor, & Tracy, 2009; Huang, McGregor, & James, 2014; 
McGregor et al., 2011; Moorman et al., 2011; Shearer, 2000). CRISP-DM breaks 
down the life cycle of a data mining project into six high-level phases, being: 1) 
business understanding, 2) data understanding, 3) data preparation, 4) modeling, 
5) evaluation and 6) deployment (Chapman et al., 2000). The sequence of phases 
is neither a strict nor linear process. Rather, the outcome of each phase 
determines which phase or specific task within a phase should be implemented 
next (Wirth & Hipp, 2000), meaning; one may have to move back and forth between 






Figure 8: CRISP-DM diagram 
Adapted from (Jensen, n.d.) 
 
Since the conceptualization and development of the initial CRISP-DM 
methodology, “the needs of data mining users, technologies available, types of 
data harvested and types of deployment have all evolved” (Hildebrandt & Gutwirth, 
2008). In response to the many environmental changes, a Special Interest Group 
(SIG) was formed to in an attempt to enhance CRISP-DM 1.0 to CRISP-DM 2.0 
(Catley et al., 2009; Hildebrandt & Gutwirth, 2008; Mariscal, Marban, & Fernandez, 
2010) in the mid-2000s although to date it appears that initiatives are no longer 
active (Vorhies, 2016). 
Catley et al. (2009) proposed that when the CRISP-DM methodology is 
applied to the healthcare industry, specifically in the context of the (neonatal) 
intensive care environment, its limitations become evident especially when it is 
used to model Intelligent Data Analysis (IDA) systems that perform Temporal Data 




of CRISP-DM methodology is inadequate in meeting the integrated needs of TDM 
making it extremely challenging, if not unfeasible to compare and evaluate systems 
from a clinical or IDA viewpoint (Catley et al., 2009). They note that despite the 
ongoing efforts to advance CRISP-DM 1.0 to CRISP-DM 2.0, there is no provision 
for multi-dimensional time series data, which is increasingly forming the data 
source for intricate DM systems that incorporates the use of Temporal Abstraction 
(TA) as a pre or post-processing step (Catley et al., 2009). 
Temporal abstractions (TA) are features or patterns of time-orientated raw 
data, a task that typically employs the use of temporal reasoning techniques 
(Fisher, Gabbay, & Vila, 2005). When the TA task is perceived as a process, it 
involves being given a set of time-stamped data, external events, and abstraction 
goals for the purpose of producing abstractions of the data that interpret past and 
present states and trends, that are pertinent for the given set of goals (Shahar, 
1997). TA is often utilized as a pre-processing step prior to DM (Catley et al., 2009).  
In the medical domain, temporal data mining (TDM) techniques are 
commonly designed either for exploration or for prediction purposes. Exploratory 
methods involve processing a database to detect groups of time series with similar 
patterns of frequent intervals and temporal relationships. To determine if they 
represent useful or previously unidentified relationships between data types may 
require or rely on the application of clinical domain knowledge to these groups or 
clusters. The target of predictive techniques may be a particular diagnosis, 
therapeutic response, or other clinical or patient care process. Such techniques 
scrutinize for combinations of intervals that often transpire with some temporal 
relationship to the target (Post & Harrison, 2008). The consent model proposed in 
this thesis enables the utilisation of NICU data for TDM activities through capture 
of surrogate consenter preferences.  
To date, the majority of NICU medical records are recorded in a manual 
manner (i.e. by hand) on paper records by health care professionals. This means 
that physiological data streams values are typically summarized once at time 
intervals (e.g. every 30 or 60 minutes). However, significantly atypical variations in 




means that constantly changing data, at a second-by-second basis often result in 
missed events and are not recorded. Research has shown that these missed 
events can be crucial in predicting survival and quality of survival free of significant 
disability (Lister et al., 2000; McGregor, 2013). In addition, neonatal research has 
advanced to the stage where the presence of specific physiological measurements 
or indicators can help forecast future physiological episodes. Consequently, 
opportunities exist to use TA-based DM to detect medical conditions prior to their 
onset via the identification of these physiological patterns and then incorporating 
them as rules within database models to allow for alert based reporting and 
actionable preventive treatments to be undertaken (Catley et al., 2009; McGregor, 
Bryan, Curry, & Tracy, 2002). 
Examination of the CRISP-DM methodology has revealed inadequacies 
particularly in a NICU context, in nearly all the phases. These include limitations in 
their ability to describe the following including: 
1. Clinically relevant and population-based information in phase 1 
(business understanding) 
2. Temporal aspects of the multidimensional data along with the clinical 
study in phase 2 (data understanding) 
3. TA of relevant details and knowledge management in phase 4 (data 
modeling) 
4. System integration in phase 4 (data modeling); CRISP 1.0 
concentrates on applying several DM techniques to arrive at one 
which offers the best results, rather than providing support for 
integration of techniques, such as DM and TA 
5. Assessment of process mining results based on temporally abstracted 
data in phase 5 (evaluation)  
6. Storage issues, knowledge sharing and representation issues in 
phase 6 (deployment), including mechanisms used for knowledge 
representation, such as adherence to health care standards 





As the number of integrated TDM systems continues to multiply, there is a 
need to extend the CRISP-DM methodology to support temporal data mining 
(Catley et al., 2009) (Catley et al., 2009). Within that extension, additional activities 
were proposed as detailed in Figure 9. Extended tasks are distinguished with an 
asterisk (*) and extended attributes are marked with double asterisks (**) (Catley 
et al., 2009). 
 
Figure 9: Extended CRISP-TDM methodology for CRISP-TDM phases  
(Catley et al. (2009)) 
 
McGregor et al. (2011) introduced the CRISP-DM into the intensive care 
environment. To support temporal DM specifically that of multidimensional time 
series DM, they extended it to create the CRISP-TDM model (Catley et al., 2009; 
Huang et al., 2014). This was accomplished via the addition of elements pertinent 
to the mining of clinical data, consisting of: 1) business understanding, 2) data 
understanding, 4) modeling, and 6) deployment phases via the utilization of the 
STDMn0 framework that enables knowledge discovery of new condition onset 
pathologies from physiological data streams (McGregor et al., 2012). 
The enhanced CRISP-DM model has been labeled as CRISP-TDM to 




data (McGregor et al., 2011). Both the CRISP-DM and CRISP-TDM models can 
be implemented in processes and sectors outside of healthcare. 
While the CRISP-TDM builds upon the standard, existing CRISP-DM model, 






























5. Database Model Design to Support Flexible, Longitudinal and 
Surrogate Consent      
This chapter presents a database design supporting research studies 
involving the analysis of patient physiological data that supports a flexible, 
longitudinal, individual and surrogate consent model. This is proposed via the 
inclusion of additional tables as an extension to the current Service Based 
Multidimensional Temporal Data Mining Framework (STDMn0). This supports three 
of the four objectives namely enabling the Consent of Infants for Neonatal 
Secondary-use research (CoINS) model to be integrated within database 
infrastructures to allow for secondary use of data research studies that analyzes 
streams of data collected from sensors in relation to patient care, instantiation of 
the consent model within a research database and demonstration of the CoINS 
consent model within an ethically approved secondary use of data research study 
where surrogate consent is required. The latter is demonstrated via a Late Onset 
Neonatal Sepsis (LONS) clinical case study in chapter 6. 
 
5.1 Data Elements Required for Capturing Consent 
 The CoINS consent model offers the primary functionalities as concluded 
from the literature review and neonatal context reviews in chapters 2 and 3 




Reason Consent model data 
requirements 
Flexibility   Allow SDM(s) to: 
1) choose their consent  
    preferences 
2) adjust their chosen consent  
    preferences at any time   
● Consent levels 
Surrogate consent Neonates are incompetent - parents or 
legal guardians often  
act as their neonate’s SDMs 
● Proxy consenter’s  
contact information  





Longitudinal consent    Allow SDM(s) to: 
1) choose their consent   
    preferences 
2) adjust their chosen consent  
    preferences at any time and  
3) ensure chosen consent  
    preferences take effect  
    immediately 
● Ability to filter out   
patients who may be 
eligible as a participant  
for a particular research 
study 
Coupled with data Ensure that consent data is coupled with 




Enable consent model to be integrated 
within database infrastructures that 
enable secondary use of data research 
studies that analyze streams of data 
collected from sensors in relation to 
patient care 
● Original STDMn0        
platform 
 
Table 5: Required functionalities, the purpose(s) of the required functionality and the consent model data 
requirements for the required functionality 
 
To allow for the functionalities of flexible, surrogate consent and longitudinal 
consent and to ensure that consent data is coupled with research study data (i.e. 
collected PHI) required the CoINS consent model to be able to identify and link the 
patient with their (surrogate) consenter, the chosen consent level of engagement 
and the research study/studies for which the patient is enrolled in. This required 







Figure 10: New tables to be added to the existing STDM n0 framework 
 
The purpose of adding each table is defined below in Table 6: 
 
Table Purpose 
Consenter ● Captures the identity and contact information of the (surrogate) 
consenter 
PatientConsenter ● Connects the patient with the (surrogate) consenter, identifies the 
(surrogate) consenter’s relationship with the patient and displays the 
consenter’s consent preference via a consent level  
Patient2Study ● Connects the patient to (a) research study/studies that they are 
consented by the (surrogate) consenter to be enrolled in and records 
the date enrollment begins 
StudyExtractStudy ● Identifies the patient profile extracted for enrollment in research 
study/studies 
ConsentLevel ● Defines the various consent level of engagement based on the 
selected available consent preference and the start date of the 
selected consent option 
● In the event that the consent level option is modified at    a later date, 
the start date will be modified to reflect the date that the change was 
implemented 
 
Table 6: New tables and the purpose of adding each specific table to be added to the original and current 





Table 7 clearly identifies the primary key(s), foreign key(s) and attributes 
associated with each of the new tables.  
Table Primary key(s) Foreign key(s) Attributes 











Patient2Study StudyID, PatientID, 
EnrollmentDate 
  
StudyExtractStudy PatientID, StudyID  ExtractionDate, 
ConsentLevel 
ConsentLevel   ConsentStartDate, 
ConsentDescription 
 
Table 7: Primary key(s), foreign key(s) and attributes for each new table to be added to the original and 
current STDM n0 database model 
 
5.2 Amended STDMn0 Architecture and Database  
This research extends the database design in STDMn0 to enable the flexible, 
longitudinal surrogate consent process as well as the ability for a patient to be 
enrolled in multiple studies. New tables were added to the STDMn0 database for 
purposes of supporting the definition of the consenter, their relationship to the 
patient and their level of consent (i.e. engagement level) at any given point in time 
noted in Figure 12 as Consent Data. Study Consent Data were added to support 
the instantiation of consent on a study-by-study basis. Consented Relative 
Temporal Data contains the patient temporal data that have been extracted from 
the clinical system for purposes of a given research study which satisfy the rules 







Figure 11: ERD of the current STDM n0 framework along with the addition of new tables (outlined in bold) 
 
The original, existing tables within the STDMn0 database are depicted on 












5.3 Amendments to the CRISP-TDM Method  
To support the population of the data within the additional STDMn0 database 
tables, additional activities are added to the CRISP-TDM’s phase 4 Modelling step. 
Implementation of a flexible consent model will significantly impact the 
consent process, affecting the data collection process and enriching the volume 
and quality of data flowing to other processes within CRISP-TDMn0. The consent 
process begins before application of the CRISP-TDMn0 approach to knowledge 
discovery. 
Flexible consent models such as the one proposed can split the general 
consent process into three phases as per the following: 
● Consent to Collect (C2C): Permission to collect patient data 
● Consent to Identify whether patient fits into research Cohort (C2IC): Based 
on the research study’s inclusion and exclusion criteria, this is permission 
to be able to review the profile of a patient to determine if they are 
(in)eligible for a particular study 
● Consent to Use (C2U): Permission to use the patient data for analysis 
 
In Catley et al. (2009), additional activities were proposed within CRISP-TDM 
as detailed in Figure 9 in section 4.5 and repeated below in Figure 13. However, 







Figure 13: Extended CRISP-TDM methodology for CRISP-TDM phases 
   (Catley et al. (2009)) 
 
Through the method proposed in this thesis, a fourth high element is added 
to the Data Modeling extensions proposed by Catley et al. (2009) to cater for 
Consent. That Consent element contains details of the consent level appropriate 
for the proposed research study together with details of the consent data for the 
data that will be used for the secondary use of data study.  
The Data Preparation step is extended with an additional process step to 
enable the consent process for data collection for the secondary use of data. In 
this case, we consider the LONS study portion only and consider the secondary 
use of the data collected previously by the Artemis Cloud Database study. The 
process begins with identifying the eligible patient population. Selection of the 
eligible patient population is based on the predetermined inclusion and exclusion 
criteria of the REB approved study. The next step is to check the SDM’s chosen 
consent level to determine if the neonatal patient’s collected health data can be 
used for secondary research. Data for consented patients is then populated within 






STDMn0 is built on the foundation of CRISP-DM and allows for knowledge 
discovery. However, its original design the database was not designed to capture 
consent. This chapter demonstrated that STDMn0 can be extended such that it can 
allow for the incorporation of a flexible, longitudinal surrogate consent process as 
well as the ability for a patient to be enrolled in multiple studies via the addition of 
tables to the existing database.  
 This chapter presents the application of the extended STDMn0 and the 
























6. Case study: Late Onset Neonatal Sepsis 
This chapter presents an instantiation of the proposed flexible consent model 
that was introduced in the previous chapter. The instantiation within the Artemis 
research database study is detailed to demonstrate the process of capturing the 
consent for that study. The results of that consenting process are then presented. 
A demonstration of its application in a LONS study at McMaster Children’s Hospital 
(MCH) is then presented... 
Artemis Cloud has been developed to provide a robust real-time cloud to 
provide health analytics as a service. The primary purpose of undertaking the 
LONS clinical study is to evaluate the deployment of Artemis Cloud and to 
demonstrate its reliability, functionality and efficacy. McMaster Children’s Hospital 
(MCH) is the first health care site providing data to the new Artemis Cloud and will 
simultaneously serve as the first real-time test of this new infrastructure that has 
the capability of storing and processing multiple channels of data provided at up to 
1000 Hz. MCH is a pediatric academic health science centre with a tertiary NICU 
located in Hamilton, Ontario, Canada (McMaster Children’s Hospital, 2018a, 
2018b; Pugh et al., 2018). The secondary use of the data collected for the LONS 
clinical study was required for the purpose of performing final validation and 
verification of the implementation of Artemis Cloud (Pugh et al., 2018) and the 
heart rate variability and respiration variability calculations used as an early onset 
detection mechanism for LONS. 
 
6.1 Implementation in Artemis 
The implementation of the flexible consent model in Artemis Cloud required 
the creation of new tables within the Persistent storage component of Artemis that 
has been instantiated in IBMs DB2 database management software. This 
component also instantiates the extended Service Based Multidimensional 
Temporal Data Mining Framework (STDMn0) framework data management 
component. The data from the consenting process for this case stay was loaded 




6.2 McMaster Children's Hospital Artemis Cloud Database 
The McMaster Children's Hospital Artemis Cloud Database (henceforth 
referred to as “Artemis Cloud Database”) is the research database created in 
collaboration between McMaster Children's Hospital and the University of Ontario 
Institute of Technology (Ontario Tech University) for the data collection part of the 
Artemis Cloud Database study. The purpose of this is a research database is to 
collect and save all the information that is produced by the neonatal patient that 
would otherwise be lost after it disappears from the monitors. This includes the 
collection of physiological data from the bedside monitors and electronic 
equipment along with clinical information from their electronic medical record 
(EMR) during the NICU stay. The information may be used for future health 
research studies in which analyzing information about the patient and other similar 
infants may help improve the future care of term and preterm infants. McMaster 
Children's Hospital (MCH) is a pediatric academic health science centre with a 
tertiary NICU located in Hamilton, Ontario, Canada (McMaster Children’s Hospital, 
2018a, 2018b; Pugh et al., 2018). 
 
6.3 Process Implemented for Artemis Cloud Database Consent 
The McMaster Children's Hospital Artemis Cloud Database study (HiREB 
3859-D) was approved on January 4, 2018. Data from the bedside monitors began 
streaming on March 9, 2018 and the date of the first SDM consent was obtained 
on March 12, 2018. At that point in time, the LONS protocol had not yet been 
approved, but the data collection for LONS study is being collected through the 
Artemis database approval. The secondary use of data study entitled Artemis 
Cloud Clinical Decision Support Framework – An algorithm to accurately detect 
late onset neonatal sepsis (HiREB 4833-C) was approved on April 26, 2019. 
The subject inclusion criteria for the Artemis Cloud Database study consisted 
of the following two requirements: 




2. Parents/guardians who have provided signed informed consent for the 
enrolment of their infant(s) into the McMaster Children's Hospital 
Artemis Cloud Database (HiREB 3859-D) 
The sole subject exclusion criteria were for infants whose parental/guardians’ 
consent for the Artemis Cloud Database is not obtained or is withdrawn. 
The sole RC responsible for obtaining surrogate consent would first review 
the neonatal admission note for each infant prior to approaching any potential 
surrogate consenter. The note provided the RC with information regarding the 
infant’s general condition and characteristics including the physical examination, 
reason for admission, the assessment and treatment plan as well as information 
regarding maternal history, labour and delivery. Given each family’s unique 
situation, the RC would then make a subjective decision as to determine whether 
or not it would be appropriate to approach the surrogate consenters regarding 
participation in the Artemis Cloud Database study. If deemed appropriate, the RC 
approached available surrogate consenter(s) to verbally explained the purpose of 
the McMaster Children's Hospital Artemis Cloud Database study and was available 
to answer any questions they may have regarding their potential infant’s/infants’ 
study enrollment before presenting them with a written Participant Information 
Sheet (Appendix B) for each of their admitted infants. In the event that (a) surrogate 
consenter(s) chose to consent their infant for the participation, they would select 
one of the two consent options as presented in the research study consent form 
(Appendix B). Figure 14 summarizes the research subject selection and consent 
process in a unified modelling language (UML) model.  














Although Artemis collects data from the moment the infant is connected to 
the bedside monitor, it did not enter the research database tables until consent 
was obtained. This meant that the surrogate consenter(s) was approached for 
consent after the admission of their neonate into the NICU and after the collection 
of their infant’s data has already commenced. Only one parent’s written consent 
was required for a neonate’s enrollment into the Artemis Cloud Database study.  
No standardized script was utilized by the RC when approaching the 
surrogate consenters. While the consent approach process remained consistent 
throughout the consent time range, there was a change with regards to the RC’s 
presentation and explanation of the available consent options during the initial 
study discussion. Initially it was explained to potential surrogate consenters why 
two consent options were available. The discussion placed emphasis on the 
privacy and confidentiality aspects of health data in a research ethics context with 
consent option 1) being presented as McMaster data and consent option 2) 
presented as data that can be linked. It was noted that there was a general 
disconnect between the surrogate consenters understanding between the privacy 
and confidentiality in a research ethics context versus how their infants’ data 
contribution would be beneficial for future research. Consequently, the later 
change involved providing parents with less technical detail about consent option 
2. Rather than focusing the discussion on explaining why there were two “yes” 
options, option 2 was presented as a practical method to facilitate longitudinal 
research by demonstrating the importance of being able to conduct future research 
on what happens to McMaster Children's Hospital's NICU infants. Unfortunately, 
the date of when this change in consent process occurred was not tracked. For 
this reason, consent option selection has been longitudinally analyzed to see if 
changes in distribution of consent option occurred over time that could be 
attributed potentially to this change in method for recruitment.  
 
6.4 Results of Artemis Cloud Database Consent 
In the span of less than one month, beginning in early March to April of 2018, 




data collection for the Artemis Cloud Database. Of the 51 beds, there were 48 beds 
in the Level 3 NICU and 3 beds in the delivery suite. Table 8 shows the exact 
dates, specific bed numbers and the total number of beds that were set up to 
collect patient data from consented patients. 
Date NICU Beds  
Were Set Up 
Specific Bed Numbers Total Number of Beds 
March 9, 2018 Bed 1 1 
March 14, 2018 Beds 2 – 10 10 
March 20, 2018 Beds 11– 20 20 
March 22, 2018 Beds 21–30 30 
April 3, 2018 
 
Beds 31-50 
● 31 – 35 at 11 am 
● 36 – 40 at 12 pm 
● 41 – 45 at 1 pm 
● 46 – 50 at 2 pm 
● 51  
50 
 
Table 8: When NICU bed spaces at McMaster Children’s Hospital were set up to acquire patient data 
collection for the Artemis Cloud Database Study 
 
The consent duration that is examined and analyzed ranged from March 12, 
2018 to December 20, 2018. During this time, there were a total of 766 unique 
admissions to the MCH’s NICU. The monthly average was 76.60 ± 6.35 
admissions. From those enrolments, A total of 239 NICU patient consents were 
received during this timeframe. Individual patients were identified by their unique 
VINES identifier (ID). Several infants who had a short NICU stay were not 
consented due to logistics of securing consent in a very short timeframe. Figure 
13 depicts the total number of unique neonatal infants who were connected to 







Figure 15: Monthly counts of unique admissions to MCH’s NICU 
 
Available patient characteristics and an explanation available for analysis are 
shown in Table 9 along with possible options or examples as applicable: 
Characteristic Explanation Options/Examples 
Vines ID Individual infant identifier  
Multiple identifier Whether infant was part   of a 
multiple birth 
Singletons, twins, triplets 
Infant identifier  Order of siblings in a multiple 
birth situation 
A or B for twins  
A, B, or C for triplets 
Biological sex  Biological character or quality 
that is assigned/determined   
at birth based on an 
individual’s gonadal, 
morphologic (internal and 
external), chromosomal and 
hormonal characteristics 
(Bockting, 2019; Planned 
Parenthood, 2020; Stedman's 
Medical Dictionary, 2004)  
Female, Male 







Calculated based on the 
addition of infant’s GA weeks 
and days 




Date of consent Date surrogate consent was 
obtained for data collection; 
this was based on the infant’s 
admission to the NICU 
 
Day-Month-Year in  
DD-Month-YYYY format 
28-Jun-2018 
Consent option Surrogate consenters can 




Option 1: Anonymous data can be used in 
combination with other similar infant’s data 
without further consent for all future studies 
that are approved by the institutional 
research ethics boards.  
 
Option 2: Infant’s information stored in this 
database may be linked using their name, 
date of birth or health card number with 
other research data sets, without seeking 
further consent from surrogate consenter. 
Future studies that are approved by the 
institutional research ethics board will be 
able to use this information. This linked data 
will be made anonymous before it is used in 
combination with other similar infants.  
 
Option 3: Consent is not given 
 
Table 9: Characteristics available for analysis regarding consented infants for the Artemis Cloud database 
study 
 
6.5 NICU Infants Characteristics 
Of the 239 infants who were consented into the Artemis Cloud Database 
study, 105 are females and 134 are males (Figure 16 and Table 10). Both graphics 
show that a higher percentage of NICU patients were consented via Option 2 





Figure 16: Breakdown of surrogate consent choices based on infant’s biological sex 
 
Biological Sex Option 1 (# and %) Option 2 (# and %) 
Female 23 (42.59%) 82 (44.32%) 
Male  31 (57.41%) 103 (55.68%)  
 54 (100%) 185 (100%) 
 
Table 10: Number and percentage of SDM’s preferred consent option choice based on biological sex of 
neonate 
 




































Figure 16: Breakdown of consented infants by types of births 
Multiple Identifier Total Number of Infants 
Singletons 171 




Table 11: Breakdown of consented infants by types of births 
The gestational age (GA) of the neonates at birth ranged from 22 weeks and 
6 days to 41 weeks and 3 days of age. The mean GA was 228.07 ± 35.24 days. 
The number of consented infants in each GA classification are summarized as 














Gestational Age Range (Week and Days) Number 
consented 
Extremely preterm < 27 weeks and 6 days 59 
Very preterm 28 weeks and 0 days - 31 weeks and 6 days 42 
Moderate preterm 32 weeks and 0 days - 33 weeks and 6 days 26 
Late preterm 34 weeks and 0 days - 36 weeks and 6 days 57 
Early term 37 weeks and 0 days - 38 weeks and 6 days 27 
Full term 39 weeks and 0 days - 40 weeks and 6 days 23 
Late term 41 weeks and 0 days - 41 weeks and 6 days 5 
Post term > 42 weeks 0 
 
Table 12: GA classification 
GA ranges confirmed based on (American College of Obstetricians and Gynecologists, 2013 [Reaffirmed 
2017]); March of Dimes, n.d.; Raju, 2017; Raju, Higgins, Stark, & Leveno, 2006; Spong, 2013; World Health 
Organization, 2018) 
 
As shown in Figure 17, a quarter of the infants consented were extremely 
preterm (25%). There were no post term infants within the consented population. 
 
 
Figure 17: Breakdown of consented infants by gestational age (GA) 
Extremely Preterm, 59, 
25%




Late Preterm, 57, 24%
Early Term, 27, 
11%
Full Term, 23, 10%
Late Term, 5, 2%





6.6 Surrogate Consenters and Consent Choices 
Of the 134 parents or guardians who consented, 40 parents (32.26%) chose 
consent option 1 and 84 parents (67.74%) chose option 2 (Table 13). Reasons for 
choosing to decline participation were not captured although the RC noted that in 
two of these cases, the parents who declined to provide consent were fathers of 
extremely preterm infants (i.e. between 25-27 weeks of GA).  
The surrogate consenters (i.e. parents or guardians) refers to those who 
provided consent levels 1 or 2 for the 239 study subjects. The majority of parents 
approached were mothers who were admitted to McMaster University Medical 
Centre (MUMC) as an inpatient. 
 
Mother’s Status Total Approached Total Consented Total Declined 
MUMC InPatient 96 89 7 
Non-Inpatient 49 45 4 
Total 145 134 11 
 
Table 13: Total number of SDMs who were approached and whether they consented or declined for their 
infant’s enrollment in the Artemis Cloud Database. SDMs (i.e. mothers) were also classified based on their 
hospital admission status 
Not all surrogate consenters were approached. However, the number of 
parents not approached and their reasons for declining consent was not tracked. 
Reasons for not approaching parents included but are not limited to: 
● Lack of adequate language skills to give informed consent on the part of 
the surrogate decision maker  
● Consideration of family stress due to post-partum maternal health issues, 
and/or neonatal instability (including planned withdrawal of 
neonatal care) 
● Family instability requiring Social Work or Children's Aid Society 
intervention 
● Inability to contact parents/guardians 





In the case of multiples, only one consent approach to a parent was made 
but resulted in the enrolment of multiple subjects. There were no cases where 
some neonates of the same multiple birth were enrolled and others were not. In 
this study, the surrogate consenter for a multiple birth made the same consent 
level preference for all of their infants. 
No analysis has been conducted to determine if there were any noticeable 
characteristics that are predictive of willingness to consent as no information on 
the consenter was collected. 
During the first month of consent in March of 2018, more infants were 
enrolled under consent Option 1. However, from April onwards, Option 2 became 
the preferred consent option (Figure 18). 
 
 
Figure 18: Total monthly consent options preferences per infant between March to December of 2018 
 
Due to small number of consents for some categories, it was not 
appropriate to stratify this monthly data into singleton, twin and triplet monthly 
analysis. Figure 19 shows the total number of surrogate consents based on the 






































































Figure 19: Total number of surrogate consents based on type of birth 
In all GA classification groups, of those infants who were enrolled in the study, 
the surrogate consenter’s preference for consent Option 2 surpasses that of Option 
1 (Table 14). Preference for consent option 1 ranged between 11.11% to 29.63% 
with an average of 22.59% (54/239) surrogate consenters choosing this option. 
Preferences for consent option 2 ranged between 70.37% to 88.89% for all patient 
groups with an average of 77.41% surrogate (185/239) consenters choosing this 
option (Table 14).  
Gestational Age 
Classification 
Consent Option 1 Consent Option 2 
Extremely preterm 22.03%     77.97%     
Very preterm 23.81%        76.19%      
Moderate preterm 19.23%     80.77%   
Late preterm 29.63%     70.37%  
Early term 11.11%    88.89%  
Full term 18.18%    81.82%  





















Type of Birth VS Surrogate Consent Options




Post term N/A N/A 
 
Table 14: Percentage breakdown of each infant’s surrogate consent options based on infant’s gestational 
age (GA) classification 
Although an infant’s date of birth and consent dates were captured in the data 
collection, it was not always clear how long each surrogate consenter required to 
make a decision about their infant’s participation in the Artemis Cloud Database 
study as some of the neonates enrolled in the study had been in the NICU prior to 
their enrollment. Figure 20 provides a visual displaying how many weeks it took 
each surrogate consenter to consent to option 1 or 2. It is clear that the bulk of 
surrogate consent is achieved during the first week of the infant’s life. 
 
 
Figure 20: Number of infants versus which week consent was received after DOB per consent options 
 
No SDMs retracted consent and withdrew from the study at any point (e.g. 
during the NICU stay, after discharge or death of their infant). 
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6.7 Application of the CRISP-TDMn0 Framework in a LONS Case Study   
The LONS study will be presented via the use of the CRISP-TDMn0 
framework as detailed:  
 
1) Business Understanding 
The first phase of CRISP-TDMn0 is to perform business understanding. This 
phase involves the identification of the Clinical Application Domain, Clinical 
Objective and Data Mining TA Goals.  
● Clinical application domain: The Level 3 NICU located at the McMaster  
Children’s Hospital (MCH), Hamilton, Ontario, Canada  
● Condition: Late onset neonatal sepsis (LONS) 
● Availability of a high dependency environment: All infants admitted to  
the Level 3 NICU at MCH 
● Patient population base: All infants admitted to the NICU at MCH will be  
eligible to be enrolled in this research study. There are no exclusion  
criteria.  
● Clinical objectives:  
o 1) To install and test an advanced minimal presence, time aligned 
high frequency physiological data platform in a busy tertiary NICU  
o 2) To gather a time aligned database of high frequency 
physiological data with time aligned low frequency medical record 
data for future studies 
o 3) To perform verification and validation of the Artemis LONS 
algorithms 
● Data mining temporal abstraction (TA) goals: Perform patient centric  
heart rate variability (HRV) and respiration rate variability (RRV) temporal  
abstractions and associate these with the suspicion and diagnosis of  
LONS  
 
Application for ethics approval was sought for the research at this stage. 




Sciences REB (HiREB 2859-D) and Ontario Tech University (#14736). Approval 
was received for the LONS study from the Hamilton Health Sciences REB (HiREB 
4833-C) and Ontario Tech University (#15536). 
 
2) Data Understanding 
The second phase of CRISP-TDMn0 is to perform Data Understanding and 
Data Preparation. Physiological and other clinical data for the LONS study was 
captured utilizing the Artemis platform.  
 
● Primary or secondary use of data: Secondary use of data 
● Data collection period: Artemis Cloud Database data collection at  
McMaster Children’s Hospital began on March 9, 2018 and the first  
consent was obtained on March 12, 2018. For purposes of this thesis,  
data collection until December 31, 2018 was analyzed. 
● Support for real-time data collection: Artemis allows for simultaneous  
real-time data collection and data analysis from bedside monitors.  
Physiological streams are captured by the Knowledge Extraction  
component of the Artemis platform. 
● Support for distributed time data collection: The Artemis Cloud  
platform is capable of supporting multi-centre studies. This research is  
based on a single site. 
● Data collection regularity: Physiological data was collected for the  
duration of the infant’s admission within the NICU provided that they  
occupied a bed space that was connected to the Artemis platform. 
● Data collection frequency: All data produced by bedside medical  
equipment at frequencies up to 1000 samples a second are captured in  
real-time 
● Streams: De-identified physiological data and clinical data that has been  
  captured in REB approved study (HiREB 2859-D) 





● Consent Data: Parental/guardian demographic data from consent forms  
(full name, consenter ID, phone number, email address and full home  
address). 
● Consent Level: Inclusion consent levels for this study are: Level 1, Level  
2 and Level 3 (see Table 15) 
● Clinical Data: patient identification (ID), date and time of birth, gestational  
age (GA) at birth, gender, birth weight, birth length and head  
circumference at birth. In addition, physiological data such as Heart Rate  
(HR) captured from the patient’s electrocardiogram (ECG), respiratory rate  
(RR), oxygen saturation (SPO2) values will be collected along with the  
associated values as well as patient events (i.e. change of bed,  
transfusion) and will include the patient event, severity value of event and  
date and time of event.  
● Patients (Subjects): All NICU patients who are admitted to the NICU at  
MCH 
● Location: MCH’s NICU  
● Primary inclusion criteria: All NICU patients who are admitted to MCH 
● Secondary inclusion criteria: NICU patients whose surrogate decision  
maker(s) (SDM(s)) have consented to the LONS study 
 
Surrogate consenters (i.e. parents or legal guardians) of all infants who were 
admitted to an Artemis bed space within the NICU at McMaster Children’s Hospital 
were individually approached by a research coordinator (RC) to allow for the usage 
of their infant’s collected data for future research purposes in the Artemis Cloud 
Database within fourteen days of their infant’s hospital admission. In the event that 
consent was not obtained within fourteen days of the infant admission to the NICU,  
then all of the infant’s data is not included within the Artemis research database 
tables 
Surrogate consent was concurrently sought for the Artemis Cloud data 
collection and for the secondary use of data for the LONS clinical study 




on the clinical management during the study and all infants received the current 
standard treatment in the NICU. 
To facilitate the surrogate consent process for the LONS case study, SDMs 
(i.e. parents or guardians) were presented with three consent levels (i.e. options) 
as follows in Table 15:  
 
Level Consent Preference 
1 
Anonymous data can be used in combination with other similar infant’s data without 
further consent for all future studies that are approved by the institutional research 
ethics boards. This means that no one will know that the information that is 
collected came from your infant. 
2 
Your infant’s information stored in this database may be linked using their name, 
date of birth or health card number with other research data sets, without seeking 
further consent from you.  
 
Future studies that are approved by the institutional research ethics board will be 
able to use this information.  This linked data will be made anonymous before it is 
used in combination with other similar infants. This means that no one outside of 
the research team will know that the information that is collected came from your 
infant. 
3 Consent not given - all buffered data will be deleted from the research system. 
 
Table 14: Description of consent preference associated with selection of consent preference level 
as presented to the infant’s SDM  
(Pugh et al., 2018) 
 
Consent was manually collected on paper for the LONS study and stored in 
a locked office at the MCH site (Pugh et al., 2018). This was due to the fixed end 
date of the project and availability of resources (i.e. the decision not to translate 
the consent form into different languages). A research coordinator (RC) then 
manually entered the SDM’s chosen consent level preference into an Excel 
spreadsheet. This resulted in a Comma Separated Value (CSV) file of consent 




All patient clinical data were stored under the unique patient’s research 
identification (VINES ID) within the research database. The translation of the 
patient’s hospital number to the VINES ID was held in a separate secure data-
table secured away from the medical record (Pugh et al., 2018). 
 
3) Data Preparation 
 As noted in the prior chapter, the Data Preparation step is extended with an 
additional process step to enable the consent process for data collection for the 
secondary use of data. In this case, we consider the LONS study portion only and 
consider the secondary use of the data collected previously by the Artemis Cloud 
study.   
The process begins with identifying the eligible patient population. Selection 
of the eligible patient population is based on the predetermined inclusion and 
exclusion criteria of the REB approved study. This requires the use of tables that 
focus on the patient and patient events (e.g. confirmation of a diagnosis). For this 
specific LONS study, there were no exclusion criteria and all neonates were 
eligible for study enrollment.  
 This study data is then populated within the related study consented data as 
the study SLONS instance of the Study Consent Data. Data for patients with consent 
level 1 would be automatically loaded into the consented datamart instance as 
study SLONS instance of a Consented Relative Temporal Data subset. Data for 
patients with consent level 2 who have indicated ‘YES’ would be automatically 
loaded into the consented datamart instance as study SLONS instance of a 
Consented Relative Temporal Data subset. This requires the use of tables that 
contain their temporal data as abstracted to create HRV and respiration rate 
variability (RRV) temporal abstractions and for those that were suspected of 
developing LONS, the relative alignment of that data as a relative distance from 
the LONS suspicion event. The time of suspicion is chosen in this case rather than 
the time of confirmation of LONS as confirmation can sometimes be as much as 





4) Data Modeling  
The Data Evaluation phase of CRISP-TDMn0 model step is beyond the scope 
of this thesis. 
 
5) Evaluation 
The second last phase of CRISP-TDMn0 model is the evaluation phase. The 
broad aim is to evaluate the clinical algorithm, software and consent model. The 
clinical and technical evaluation is beyond the scope of this thesis. 
 
6) Deployment 
The final phase of CRISP-TDMn0 is deployment. This stage is outside the 
scope of this thesis. 
 
6.8 Application of Extended STDMn0 to a Retrospective LONS Case Study  
In the previous chapter, five new tables were proposed to be added to the 
current STDMn0 framework to capture the necessary data required to support the 
flexible consent process with additional functionality for that to be provided by a 
surrogate. These tables were related to the identity of the consenter, the linking of 
the consenter to the patient, the selected consent level preference, the extraction 
of the patient for a study based on consent level and the linking of the patient to 
specific research studies based on the selected consent level associated with the 
patient. 
The following steps demonstrate how the extended STDMn0 can be used to 
select potential neonatal patients who are eligible for a retrospective study from a 





Figure 21: How to filter for potential neonatal patients who are eligible for a LONS retrospective study from a 
researcher’s perspective. 
6.9 Summary 
This research demonstrates the use of the consent model proposed within 
the context of a retrospective research study to investigate whether there are 
common patterns in physiological data before the clinical suspicion and diagnosis 







7. Discussion   
This chapter discusses issues related to the results presented in chapter 6, 
within the context of the additional functionalities provided by the Consent of 
Infants for Neonatal Secondary-use research (CoINS) model. Here we further 
discuss how consent, and research data made accessible by that consent, are 
coupled within the Service Based Multidimensional Temporal Data Mining 
Framework (STDMn0) platform and how these are implemented by Artemis in a 
systemic platform that supports multiple concurrent research studies. This chapter 
also highlights changes made to the study protocol and any identified limitations. 
 
7.1 Flexible Consent 
CoINS offers multi-level participant consent allowing surrogate decision-
makers (SDMs) to select consent preferences from a potentially wide range of 
options. Within the Artemis Cloud Database study, while consent option 2 was the 
most popular option selected by SDMs, there are still those who selected option 1, 
or who chose not to consent at all. This emphasizes the importance of providing 
parents with the ability to choose among a variety of available consent options as 
a ‘one size fits all’ approach to the consent process does not exist. Additionally, 
the high consent rates support results previously seen in adult studies in that many 
SDMs also accept that secondary use of their personal EHR data in research 
contributes positively to the community (Hill et al, 2013), and generally see health 
research as valuable and unproblematic (Vermeulen et al, 2009). Also, and 
perhaps most notably, that they appreciate an opportunity to decide on research 
participation on behalf of their infant, thus emphasizing the importance of the 
flexibility functionality of the CoINS model. This also reinforces prior research 
findings that most parents were displeased when the consent requirement is 
supplanted by blanket approvals for distribution of health data made by an ethics 
committee, leading to enrollment of children in studies absent disclosure or 




that they did not want their newborn to be enrolled in studies without their consent, 
even if it was considered to be low risk, such as that of a data collection study. 
 
7.2 Surrogate Consent 
In order to capture surrogate consent, the research system is required to 
capture the consenter’s information and their chosen consent preference, which 
must both be linked to the record of the individual patient.  
 
7.2 Longitudinal Consent 
CoINS provides an ability to capture longitudinal consent, that is, consent 
which can be altered by the participant over time as their circumstances and 
preferences change. Requesting additional consent for future studies is costly in 
terms of time, effort and resources. There can also be a significant loss of 
participants over time as people’s contact details change (Kaye et al., 2015). With 
CoINS, SDMs are offered the option to provide broad consent to allow anonymous 
data linking for all future studies that are approved by institutional research ethics 
boards (REBs), meaning that should they so choose, re-consent with each new 
research study would not be necessary. Some SDMs may choose to update their 
consent preferences throughout the life of the Artemis Cloud Database study, as 
the data is consented for use until the child attains 18 years of age. CoINS enables 
recording of these updated consent preferences and ensures the most recent level 
of consent is applied when assessing whether an infant’s data may be included in 
each new component of the wider study.  
 
7.3 Coupling Consent and Research Data 
Within the Artemis database, consent and research data is linked, together 
with the SDM’s contact information, with the patient record during the consent 
process. In that way, the SDM’s consent preferences are indelibly linked to the 
patient. Whenever an approved researcher filters for potential research 
participants, the individual neonatal patient is either included as part of the 




7.4 Coupling Consent and Research Data within an IT Solution 
There are numerous advantages of implementing an IT-based consent 
solution. All participant information (including consent preferences) are 
conveniently stored within an accessible interface for researchers and SDMs. 
Specific consent provisions travel with a participant or donor’s data and samples 
as they are shared or accessed for different purposes – in the case of this thesis, 
for different studies. These consent provisions can be electronically and 
cryptographically “wrapped” with the donor’s samples and information (Kaye et al., 
2015). Should the SDM wish to retract consent, their infant’s data can immediately 
be excluded from the research system whilst still remaining in its original location 
in the clinical system, thus not affecting ongoing treatment. 
Furthermore, as a systematic IT platform already exists, future improvements 
to the proposed consent model can allow for development and incorporation of 
features that extend the solution with broader consent options. For example, an 
ability to filter for and choose one’s preferred categories of research, for example: 
clinical trials, genetic research, public health research, observational studies, 
research related to particular medical conditions or illnesses. Other examples 
might include allowing the choice to participate in research conducted by 
commercial organizations, or to request general research results either as a simple 
‘thank you’ acknowledgment for their contribution and involvement, or 
demonstrating how their samples and information have been useful (Kaye et al., 
2015) thus encouraging future participation and engendering transparency 
between researchers and participants. This would improve the public’s 
understanding and trust for secondary use research using collected health data 
and samples and could potentially lead to higher consent rates. 
 
7.5 Changes to and Limitations of the Study          
It was initially proposed that four consent levels be offered to the neonate’s 
SDM. This would have included all of the options as shown under the “consent 
option” in Table 12 along with the choice that “the parent/guardian of the infant 




in a new research study”. However, McMaster Children’s Hospital (MCH)’s 
neonatal research committee deemed that offering such a broad degree of 
individual consent was far too labor intensive to implement for the entire study. 
They proposed to conduct a separate study assessing the percentage of uptake 
should this option be available. Removal of this option meant it was not possible 
to implement and evaluate the original flexible consent model. However, results 
still showed parents were willing to contribute to this research.  
As discussed in Section 6.3, there was no standardized script and subtle 
changes were made by the research coordinator (RC) during the consent 
approach explanation to surrogate decision makers (SDMs). Initially when 
presenting the study to parents, the RC focussed on explaining why two ‘yes to 
consent’ options were available, and emphasis was placed on the privacy and 
confidentiality of data collection in a research ethics context as part of that 
explanation. The changes involved explaining that the second option was a way to 
better facilitated longitudinal research (e.g. for purposes of doing future research 
on what happens to MCH’s NICU infants). The changes resulted from the RC 
noticing SDMs’ slight confusion between the two available consent options as they 
were not as aware that data usage in option two was still anonymous despite 
linkage in the database to ensure consent (i.e. it is emphasized that results 
dissemination is still anonymous). Consequently, by providing the information in 
more relatable and easily understood terms, it was felt this change would result in 
increased participation via the second consent option. This hypothesis has proven 
difficult to substantiate as, by default, option 2 was already the popular option 
(Figures 18 and 20). It is unfortunate that the date of when this change in the 
process was applied was not tracked. For this reason, consent option selection 
has been longitudinally analyzed to monitor for changes in distribution of consent 
option as they occurred, and which might be attributed to this change in recruitment 
approach. Apart from choosing between consent options, no parents have made 
requests to exclude specific types of data or asked for specific data to be removed 




7.6 Limitations Regarding Data Collection  
Most results from the data collected during this study reflect the 
demographics of the infants who were consented for the study and do not actually 
reflect whether SDMs would use the CoINS model or demonstrate the nuances of 
how the proposed consent model would function in reality. Additionally, having 
many multiple births in a month can also skew the data as SDMs tended to choose 
the same consent level for all infants over which they exercise responsibility. Many 
neonates are admitted to the NICU after premature births, which puts them at 
greater risks for congenital or emergent complications. To better understand users 
of the CoINS model, it would be useful to examine the range of medical conditions 
these neonates were diagnosed with to consider whether their condition affects 
their SDM’s decision for participation in research.  
Either parent’s written consent was all that was necessary to enrol a neonate 
in the Artemis Cloud Database study. It is unclear if only birth mothers were 
approached or if fathers (or a second partner) consented. The rationale for this 
was because it was not uncommon for only one parent (usually the mother) to have 
sole care and custody of the child, which meant consent from a second parent was 
believed to not be necessary. In situations where neonates are in custody of the 
Children’s Aid Society (CAS) or Catholic Children's Aid Society (CCAS), it was 
technically possible to seek consent for their participation in research studies. 
However, this is often discouraged by the research ethics board for two reasons 
relating to: (a) potential legal implications should the custody status of the child 
change in the future, and (b) practicality issues, as it is usually very difficult to 
arrange to obtain consent from case or social workers. In the event that an infant 
had two parents it is not known whether there were situations where one parent 
consented for one infant while the second parent consent for the sibling. Certain 
data was not tracked, including the number of parents not approached and the 
reasons of those parents who declined consent to participate. It is also unclear 
from the data if there were SDMs who provided and later revoked consent, and if 
so, how soon revocation occurred. If any reasons for revoking consent are 




significant to processes for further improvement of the consent model and process. 
Similarly, it is also unclear if any SDMs declined consent when approached initially, 
but later went on to consent for the usage of their infant’s data. Should SDMs have 
chosen to change their consent preference, it would have been demonstrative of 
the practicality of CoINS to accommodate such flexibility. These data should be 




























This thesis presented the Consent of Infants for Neonatal Secondary-use 
research (CoINS) model, which we believe is the first proposed flexible and 
longitudinal consent model targeted to the secondary use of physiological data for 
medical research studies and incorporating the ability for surrogate consent. 
CoINS offers a range of consumer engagement features as drawn from the 
PF4SUMD model (Heath, 2012), and incorporating the flexibility of MC. The CoINS 
consent model can be integrated and instantiated within a research database of 
the Artemis platform. CoINS is suitable for use in any healthcare environment 
supporting secondary use of patient data in research studies including those 
seeking to analyse streaming data collected from physiometric sensors. Use of 
CoINS was demonstrated as part of ethically approved secondary use research 
where surrogate consent was collected using the application for the retrospective 
Late Onset Neonatal Sepsis (LONS) study at McMaster Children’s Hospital 
 
8.1. Thesis Contributions 
This thesis presents the following contributions:  
1) An up-to-date review of existing consent models; 
2) The CoINS consent model; 
3) Demonstration and evaluation of CoINS applied to a retrospective study in 
a neonatal intensive care environment. 
 
The following research objectives were addressed in the chapters:  
1) Creation of CoINS, a flexible multi-level consent model enabling the 
research participant to adapt consent preferences as their wishes change, 
along with the ability to do the same with regard to surrogate consent for 
minor children in their care (chapter 5); 
2) Development of an approach for integrating CoINS within databases 
supporting secondary use of data in research studies, including analysis of 





3) Instantiate that model within a research database (chapter 5) 
4) Demonstrate the use of that model within an ethically approved secondary 
use of data research study where surrogate consent is required (chapter 
6) 
 
8.2 Future work 
Additional functionality to allow consenters to pick "how" and "when" consent 
is given in a more holistic way may be developed to further develop CoINS. Given 
the relative recency of the Artemis Cloud Database study, the consent options 
offered presently only apply to prospective, not retrospective, consent, it will take 
time to see how many SDM’s will take advantage of the ability to alter their consent 
retrospectively. Additionally, the existing CoINS model is intended for use in a 
single site setting and not tested in a multi-site environment. However, successful 
implementation of any novel or non-traditional consent model will require change 
management and the cooperation and feedback of the responsible research ethics 
board, IT department and researchers who will use the collected data. End users 
(e.g. patients and substitute decision makers) contributing their 
neonate’s/neonates’ data would also need to be engaged in this process. We 
propose that Patient and Public Involvement (PPI) sessions would be required to 
ensure that developers of these solutions understand and anticipate how non-
clinical users engage with these systems.  
Many neonates have two parent SDMs, and it is possible that one parent may 
agree while the other disapproves providing consent to allow the use of their child’s 
clinical data in research. A multidisciplinary team including bioethicists, lawyers, 
PPI representatives and clinical staff would be required to develop protocols to 
address this and other exceptional situations as and when they arise.  
Some related topics and issues did not fall within the scope of this thesis and 
were not examined. These include approaches for informed consent and the 
ongoing ethical issues of ‘ownership’ of the clinical record and ‘monetising’ of what 
may be valuable consented or donated data. It may also be difficult to know 




informed consent and their degree of comprehension regarding the purpose for 
undertaking the study and uses to which their child’s data may be applied. 
CoINS is capable of expansion beyond serving as a consent model that 
identifies and links patients and SDMs, potential research participants, and 
researchers who may require their data. After successful implementation of a 
modernised consent model, the model should be expanded to become a platform 
that promotes communication and transparency of research and results to SDMs 
(and children as they age and achieve Gillick competence).  
There is little doubt that when a person or their child requires hospitalization, 
it can be an extremely distressing time for loved ones. Ethical and emotional 
questions regarding appropriateness must also be considered: When is the most 
appropriate time to introduce parents to the CoINS concept; when should be 
approached regarding consent to access to their or their child’s health data; and 
whether parents of stillborn or neonates who have died during the NICU stay 
should be approached at all.  
Informed consent is a dynamic process that requires the engagement and 
partnership of multiple stakeholders including the donor or consenter, collectors, 
and users of the data. While the donor and/or consenter may be the same 
individual in the case of a competent adult, this is not the case in the NICU where 
a surrogate consenter is required. A flexible, longitudinal consent model that 
encourages parental autonomy that caters to proxy consent such as surrogate 
consent and leverages the use of information technology (IT) tools that are already 
collecting streams of data collected from patient care sensors would potentially 
encourage more surrogate decisions makers to enroll their infants in research 
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Appendix A – Description of Consent Models 
 
 
       Consent 
         Model 
Description                    Advantages and  
                    Disadvantages 
 Flexibility   Longitudinal     
  engagement 
Multi- 
   level 
     Proxy 
   consent 
    Coupled 







parents for a study at 
the time that the 
infant becomes 
eligible. SDMs are 
provided with verbal 
and written 
information and 
encouraged to ask 
questions before 
they make a decision 
to participate. If they 
consent to participate 
in the study, they 
must sign a consent 
form. [7] 
(+) Most common and widely used 
consent model; familiar process to 
many researchers [1][7] 
 
(-) Participants’/ SDMs’ decisions may 
change after initial consent 
 
(-) A variety of decisions are made at a 
single point in time [1] 
 
(-) Explaining study information can add 
on to a potentially lengthy and complex 
consent process [1] 
 
(-) Difficult to apply when time is limited 
(e.g. in studies involving emergency 
scenarios or procedures) [7] 
 
(-) May lead to decreased enrollment 
due to invasiveness of research 
protocols, lack of benefit for the infant 
enrolled, and/or the infant’s illness 
severity [7] 
 
(-) Negative impact of formal wording 
utilized in written information and 
consent forms [7] 
 
(-) Participants/SDMs may experience 
information overload regarding a study 
and potential incidental findings [1] 
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Description                    Advantages and  
                    Disadvantages 
 Flexibility   Longitudinal     
  engagement 
Multi- 
   level 
     Proxy 
   consent 
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parents in advance of 
their infant’s eligibility 
for a study. Parents 
are solicited in 
anticipation that their 
infant will meet the 
study inclusion 
criteria at a future 
date. [7] 
 
Often used prior to 





Most suitable for 
studies that involve 
the immediate 
postnatal period [7] 
(-) Possibility of overburdening parents 
with unnecessary information in the 
situation that their infant does not meet 
the study’s inclusion criteria especially 
in situations where parents are given 
information about neonatal studies in 
the prenatal period and maternal 
studies are solicited simultaneously [7] 
[12] 
 
(-) Not possible to know with certainty 
when an infant will be eligible for many 
studies; possibility that parents may not 
be able to recall the specific details of a 
study or perhaps ever being 
approached for consent at all, following 
their infant’s birth [7] 
 
(-) Not recommended for majority of 
studies in the NICU environment [7] 
 
(-) Validity of consent obtained during 
labour is questionable [12] 
 
(-) Obtaining consent from high risk 
pregnancies may put undue stress on 
parents [12] 
   










collected sample (or 




provide consent once 
and entrust 
researchers and 
ethics committees to 
review and approve 
(+) One-time consent simplifies the 
research process [3] 
 
(-) Legal challenges associated with 
blanket consent models have been 
underplayed [3] 
 
(-) As blanket consents are necessarily 
vague, they are too general to have 
much legal weight [3] 
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         Model 
Description                    Advantages and  
                    Disadvantages 
 Flexibility   Longitudinal     
  engagement 
Multi- 
   level 
     Proxy 
   consent 
    Coupled 
    with data 
any future research 
projects [19] 
(-) Do not allow patients to act 
meaningfully on their continuing right to 
control their health information [3] 
 
(-) Samples or data may be used in 
future studies that conflict with an 
individual’s fundamental values [3] 
 
(-) Does not provide participants with 
the ability to control the specific projects 
as to which their samples/data are to be 
used in; an independent body (e.g. 
REB) makes these decisions on behalf 
of the individual who provides consent 
Bona fide  
consent 
A patient makes 
informed consent 
after a collaborative 
discussion with the 
clinician [5][6] 
 
     
Broad consent A process by which 
an individual donates 
their samples (or 
data) for a broad 
range of future 




An individual is 
provided the option 
of consenting to 
future research of a 
particular type with 
regards to both 
content and context 
rather than to just a 
specific research 
project [19] 
(+) A broad consent restriction may be 
that if certain types of research are 
known to conflict with the participant’s 
fundamental values, this could be 
precluded at the point of initial consent 
[19]  
 
(-) Does not provide participants with 
the ability to control the specific projects 
as to which their samples/data are to be 
used in; an independent body (e.g. 
REB) makes these decisions on behalf 
of the individual who provides consent 
 
(-) No regard to future uses when 
consenting; Future uses do not 
constitute valid informed consent 
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Description                    Advantages and  
                    Disadvantages 
 Flexibility   Longitudinal     
  engagement 
Multi- 
   level 
     Proxy 
   consent 
    Coupled 
    with data 
Cascading  
consent 
A process that offers 
donors successive 
choices, starting with 
blanket consent as 
the default (e.g. 
those who are 
uncomfortable with 
blanket consent 
could be offered 
“broad” consent. If 
the donor objects, 
then they may be 
offered the chance to 
opt out of certain 
forms of research, or, 
offered the chance to 
opt in to certain types 
of research) by using 
computing 
technology [9] 
(+) As part of a cascade of choices, 
“broad” consent may be an efficient 
way to cluster likely objections without 
being too cognitively burdensome on 
patients. By retaining the full range of 
potential consent scope, from blanket 
to opt-in, the regime can better respect 
autonomy and reflect donor 
preferences. [9] 
 
(+) Nudges subjects toward blanket 
consent while retaining options for 
donors who would prefer a more limited 
form of consent. This may help 
biobanks minimize costs and maximize 
use of their samples. [9] 
 
(-) Some donors may want to only allow 
work on a particular disease affecting 
their family. Some biobanks may find 
that it is not cost-effective to accept 
such restricted samples, and 
consequently may decline to accept 
them. [9] 
 
(+) Yet there are likely instances in 
which a specimen is so important to 
research that narrow consent is better 
than none at all. [9] 









Board (IRB)/ Ethics 
Review Board (ERB) 
examining trials on 
(-) Ethical and practicality concerns: 
• Questionable if REBs should 
make decisions for individuals 
considering how preoccupied they 
already are [7] 
• REBs cannot know the specific 
detail regarding each and every 
case or participant situation [7] 
   
        
        X  
   (not by  
    family/ 
     legal  





       Consent 
         Model 
Description                    Advantages and  
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Multi- 
   level 
     Proxy 
   consent 
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    with data 
behalf of potential 
patient subjects [7] 
 
The REB makes a 
decision on behalf of 
individual patients 
that are eligible for 
the study (i.e. on a 
case by case basis) 
[7] 
• Likely that REBs are unable to 
make decisions within some given 
timeframes [7] 
• In non-emergency situations, 
health care professionals are 
restrained from making decisions 




An individual is 
presented with a 
“menu” of choices 
and a response is 
elicited. This menu 
may be accompanied 
by a large quantity of 
information, most of 
which is not specific 
to patient or on the 
other extreme, little 
or no information 
may be provided. [6] 
(-) Emphasis of contrived consent is not 
on ensuring the patient's understanding 
of information but on his/her indication 
that clinician may proceed with the 
proposed procedure or treatment. [6] 
     
Deferred  
consent 
Legislation in certain 
countries permit 
research without 
prior consent when 
the following 
conditions are met 
[20]:  
1) treatment is  
    required urgently;  
2) urgent action is  
    required for the  
    purposes of the  
    trial 
3) it is not reasonably  
    practicable to  
(+) Seeking informed consent requires 
time which is limited in emergencies 
when even minimal treatment delays 
can be harmful to the patient [20] 
 
(+) Parent(s)/guardian(s) are not 
always present when a child requires 
emergency treatment or a mother of a 
critically ill neonate may be sedated 
 
(-) Clinicians with no experience of 
research without prior consent may be 
concerned that this model would be 
detrimental to the parent–practitioner 
relationship. In nations such as the 
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    obtain consent  
    prospectively; and  
   4) an ethics  
       committee has  
       approved the  
       consent procedure 
 
A child research 
subject will have 
already received an 
intervention as part of 
a trial before any 
information is 
provided or consent 
is sought. 
Fundamentally 
permission is sought 
post-intervention to 
use data that have 
already been 
collected and 
consent for the child 
research subject to 
continue to take part 
in the trial. [20] 
 
United States and those in the 
European Union, informed consent can 
only occur prior to enrollment.  
“Deferred” consent is not an acceptable 
term. Consequently, the waiver of 
consent process is the only available 
alternative. [18] 
 
(-) Removes parents’ (and children’s) 
autonomy [10] 
 
(+) In contrast, practitioners with 
experience of this consent model 
described how families were receptive 
to the method as long as discussions 
were appropriately timed and 
demonstrated sensitively. [20] 
Mandatory  
Return 
Advise participants at 
time of consent of 
mandatory issues or 
items that may be 
returned regardless 
of consent to return 
findings. [1] 
 
(+) Researchers’ obligations to return 
incidental findings are clearly defined 
from the beginning of consent process 
[1] 
 
(-) Considerable information about 
possible findings and how they would be 
dealt with will need to be provided as 
part of the initial consent process. [1] 
 
(-) Individuals’ choices about receiving 
incidental findings are restricted 




       Consent 
         Model 
Description                    Advantages and  
                    Disadvantages 
 Flexibility   Longitudinal     
  engagement 
Multi- 
   level 
     Proxy 
   consent 
    Coupled 
    with data 
to those findings they desire to receive 
and those they would rather not 
know about, leading to disclosures 
that could be both under-  
and overinclusive, depending on  
their preferences. [1] 
• May discourage  
study           enrollment [1] 
 
(-) Re-contacting participants is costly in 





disclosure of data 
originating from a 
confidential 
relationship (i.e. their 




emerges from any 
future research on 
their data set, the 
information content 
of which cannot be 
predicted. [10] 
(+) The leading moral principle is 
veracity which should precede 
autonomy [10] 
 
(-) No promises of anonymity, privacy or 
confidentiality are made [10] 
 
(-) Donor’s data could be included in an 
open-access public database [10] 
 
(-) Participation involves a certain risk 
of harm to themselves and their 
relatives [10] 
 
(-) Participation does not benefit the 
participants in any tangible way. [10] 
 
(-) While withdrawal from the study is 
possible at any time, complete removal 
of data that have been available in the 
public domain may not be possible [10] 
            X  
Opting out Parental consent is 
presumed. An 
eligible infant is 
automatically 
enrolled unless the 
(+) Attempts to lessen parental distress 
by removing some of the decision-
making on behalf of their infant, as they 
are not solicited for their consent [7] 
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parents explicitly 




(+) Results in the generation of valuable 
knowledge earlier due to increased 
enrolment [7] 
 
(-) Does not respect parental autonomy 
[7] 
 
(-) May negatively affect parents’ 
perception of the study as they may be 
under the impression that the 
experimental intervention is equivalent 
to treatment that is provided to their 
infant is the health care unit/facility (in 
the case that the study is a clinical trial) 
and/or the possibility of thinking that 
asking for their permission to enroll 




their own raw data 
and allow them to 
take to another 
specialist who can 
assist them to decide 
what information they 
want returned from 
the study. [1] 
(+) Participants are spared from the 
immediate task of deciding which 
findings to receive and allows them to 
choose their own services to interpret 
their own raw data if they wish [1] 
 
(+) No need to address issues such as 
return of incidental findings thus saving 
time and costs [1] 
 
(+) Researchers have less obligations 
[1] 
 
(-) Participants who do not use an 
interpretive service may not learn of 
medically significant data – however 
interpretive services are not widely 
available and accessible to everyone 
[1] 
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   level 
     Proxy 
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    with data 
(-) Without readily accessible 
interpretive genetic services, the 




Parental consent is 
not sought prior to 
enrolling their infant 
in a study. [7] 
(+) Removes the decision-making 
burden from the parents [7] 
 
(-) Parental autonomy is not 
considered. This issue can be 
extremely sensitive and controversial in 
certain situations, such as when a study 
involves experimental options for 
different treatments that have different 
risks and benefits compared to other 
treatment options that may be 
available. [7] 
 
(-) Unlike a clinical trial, the secondary 
use of physiometric data collected from 
infants may not have an immediate 
effect on their treatment or result in a 
life or death situation. However, it fails 
to comply with laws in many 
jurisdictions that relate to consent, 
parental autonomy and surrogate 
decision-making. [7] 
 
(-) May increase stress if parents are 
concerned that their child has been 
enrolled in a study without their 
knowledge [7]; made worse if they find 
out years later as seen with 
unconsented Guthrie test use in several 
countries. [4] 
 
(-) Parents may make the assumption 
that the entire NICU supports the 
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research that is being done and will 
place a certain level of  
responsibility regarding  
the research on all health care 






randomized for the 
purpose of 
comparing two 
standard methods of 
treatment without 
parental knowledge 
or consent. [7] 
 
The purpose of such 
a trial is to contrast 
two treatment 
approaches, each of 
which is deemed to 
be acceptable clinical 
practice which can 
be individually 
implemented without 
involvement of the 
parents. [7] [13] 
 
Similar to the 
presumed consent 
model. [7] 
(+) Alleviate the stressful burden 
associated with decision-making from 
the parents from what would otherwise 
have been routine practice [7] 
 
(-) Does not take into account parental 
autonomy [7] 
      




by the REB. [7] 
 
Typically, this is done 
for innocuous studies 
that are assessed as 
presenting minimal 
(+) Removal of some of the decision-
making burden on the parents of having 
to make a decision on behalf of their 
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accepted in NICU 
research practice, 
this model may be 






and/or in situations 
where the research 
could not be 
practicably 
accomplished 
without the waiver. In 
such situations, the 
subjects (or their 
surrogate decision 
maker) should be 
provided with the 
additional relevant 
information after 








use of health data or 
sample along with a 
request for consent is 
provided to the 
individual via a web-
based platform. [8] 
(+) DC is currently a biobanking project 
but has the ability to be expanded to 
other applications and fields [8] 
 
(+) In the case where there are multiple 
researchers and research projects, it is 
difficult to obtain informed consent for 
all future research uses at the time of 
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Every request for 
consent would be 
presented with a 
description of the 
entire project. [8] 
 
recruitment into the biobank or before 
such research commences. DC 
recognizes that the expression of 
individual autonomy is also not static: it 
involves making choices and decisions, 
such as the decision to consent to 
participate in research, over the course 
of one’s lifetime [8] 
 
(+) Individuals could provide different 
types of consent depending upon the 
kind of study. These consent 
preferences travel securely with their 
samples or data so that third parties 
know the scope of the consent that 
applies. [8] 
 
(+) A secure consent interface allows 
participants to [8]:   
• Modify their consent preferences 
reliably [8] 
• Alter their contact details [8 
• Receive information on the use of 
their samples and data [8] 
• Enroll in new studies [8] 
• Complete online surveys [8] 
• Engage with the research study in 
their own time, as often or as little 
as they choose [8] 
 
(+) Available preferences can be 
adapted to suit the capabilities and 
needs of institutions, researchers and 
participants [8] 
 
(+) Could enable researchers to gain a 
better sense of participants’ views on 
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provide the opportunity for participants 
to be better informed and to set specific 
preferences relating to what feedback 
they would like, and when and how it is 
received [8] 
 
(-) Requires cultural change for both 
health-care professionals and 
individuals. It requires partnerships for 
health that are open, transparent and 
engaging, and which understand and 
value the central role that patients have 
in research as the providers of 
information and biological material. [8] 
 
(-) Requires an investment of resources 
such as time, money, expertise and a 
commitment to such a vision by 
clinicians and researchers, health-care 
services, research institutions and 
governments is necessary for [8]:  
• Development of new policies, 
standards and ways of working 
that can accompany this 
approach [14] 
• System must have the technical 
capacity to interface with the 
systems of the various research 
organizations so it can provide 
information and feedback [8] 
 
(-) Online services run the risk of 
excluding individuals and communities 
with limited or no internet access [8]  
 
(-) New processes and technology for 
testing and monitoring the integrity of 
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provide operational control for 
managing risk throughout the lifetime of 
the data holding [8] 
 
(-) Not all potential participants will 
connect and opt in  
 
(-) Not practical for research using 
routine clinical data   
 
(-) Every request requires description of 
entire project; May result in consent 
fatigue [8] 
Meta Consent  
(MC) 
MC denotes the idea 
that individuals 
should be asked how 
and when they would 
like to provide 
consent [16] 
 
Allows an individual 
to choose their 
preferred consent 
model (i.e. broad 
consent/refusal, 
dynamic consent, 
blanket consent or 
refusal) for different 




data or data that will 
be collected in the 
future via a web-
based platform (i.e. 
retrospective and 
prospective). [14] 
(+) Combines the broad and dynamic 
models, with additional options for 
blanket consent and blanket refusal 
[14]   
 
(+) One can choose how and when they 
wish to provide consent for future 
secondary research of data collected in 
the past or of data that will be stored in 
the future (i.e. MC is both retrospective 
and prospective) [14]  [15] 
 
(+) Individuals can choose the type of 
consent: DC, broad consent, blanket 
consent/refusal for different types of 
research [14] 
 
(-) Costs and burdens of such a 
framework; may be much higher than 
asking participants to reconsent [11] 
 
• (-) Need to take care to avoid false 
positives where those who chose broad 
consent are contacted by mistake [11] 
•  
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MC denotes the idea 
that individuals 
should be asked how 
and when they would 









technology based on 
individual’s 
preferences. 
• (-) Problem of what to do when 
participants fail to reply [11] 
• (+) Failure to provide MC could be 
handled in several ways (e.g. MC 
could be arranged early in life, 
which could be achieved by making 
it mandatory as an individual comes 
of age, the individual could receive 
reminders from healthcare 
professionals when seeking 
treatment, reminders could be 
linked to the use of various official 
web services, or a default position 
of broad consent could be applied). 
[14] 
 
• (-) Administrative systems need to be in 
place to track, and accurately respond 
to, individual fine-tuned choices [11] 
•  
• (-) Online services run the risk of 
excluding individuals and communities 




Obtain consent in 
stages, with brief 
mention of incidental 
findings at the time of 
initial consent but 
with more detailed 
consent obtained if 
and when reportable 
results are found [1] 
(+) Staged approaches allow 
participants to retain control [1]  
 
(-) However, when a decision is 
deferred until findings exist, the door is 
open to communication of unwanted 
information about potential risks. The 
likelihood of such findings will vary 
across studies, depending on the scope 
of reportable results defined in each 
protocol. [1] 
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(+) Various alternatives have been 
proposed for this model, including:  
• Obtaining consent to return of 
incidental findings at the time of 
enrollment would be to defer the 
process of decision-making about 
returning them until later in the 
process 
• Postpone the process regarding 
decisions about receipt of incidental 
findings until it was clear whether 
there would be such findings for a 
given participant. 
• When consent to participation was 
obtained, participants would be told 
that incidental findings might be 
detected in the relevant categories 
and that they would be given an 
opportunity, if such results were 
found, to learn more about them 
and decide whether to receive 
them.  
 
(-) Participants/SDMs decide whether 
to enroll in a study without receiving full 
information regarding incidental 
findings [1] 
 
(-) Effectiveness partly depends on 
funding to create the infrastructure on 
for a system for communicating with 
participants, soliciting preferences, and 
returning information over time [1] 
 
(-) Re-contacting and following up with 
participants/SDMs could be challenging 
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(-) In certain types of studies, the act of 
re-contacting the participant/ SDM can 
reveal unwanted information [1]  
Tiered  
Consent 
Provide patient with 
Generic consent as 
Tier 1, then as Tier 2 
provide them with 
specific content to 




(+) Allows for some tailoring to 
participant’s consent preferences 
         X   
Binned  
Consent 
Where a large 
amount of 
information is 
relevant to consent, 
this information is 
divided into smaller 
'bins' of relevant 
information. [2] 
(+) Approach was proposed as a 
framework to organize genes to 
consider the return of incidental 
findings in genomic studies [2] 
 
(+) Binning genes could also be a 
useful approach for consent and patient 
education [2] 
 
(+) Rather than providing specific risks 
for each individual gene, genes can be 
organized into bins, defined by their 
risk, clinical utility, evidence supporting 
medical management, or other relevant 
features [2] 





information areas are 
divided into bins. A 
generic Tier 1 is 
developed from each 
bin and the 
combination of all tier 
1's are presented to 
the participant/ 
patient and they are 
asked if they prefer 
(+) Combines tiered and binned 
consent for those who wish to have 
more information [2] 
 
(+) Minimize information overload and 
support informed decision making  
   [2] 
 
(-) Consent model initially designed to 
evaluate the outcomes of receipt of 
multiplex testing for cancer 
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more information on 
each item during the 
tier 1 presentation. 
[2] 
susceptibility; however, the outcomes 
of the tiered-binned approach are 
currently unknown. [2]  
 
(-) This model is proposed for genetic 
susceptibility testing for common 
cancers and may not apply in other 
contexts, such as genetic testing for 
rare cancers, for which panels are 
commonly utilized and do not have the 
same wide variability in the disease 
spectrum, risks, or management 
options.  [2] 
 
(-) Designers of model debated the 
merits of providing specific information 
for particular genes when patients have 
expressed varying testing 
preferences.32 The value of utilizing 
specific examples remains unknown. 
[2] 
There is also value in evaluating 
various visual formats and content of 
risk information, particularly among 
populations of varying genomic literacy 
[2] 
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